

FORM PTO-1390 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 10-95)		ATTORNEY'S DOCKET NUMBER BB-1386
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR) 10/019633
INTERNATIONAL APPLICATION NO. PCT/US00/21009	INTERNATIONAL FILING DATE 28 JULY 2000 (28.07.00)	PRIORITY DATE CLAIMED 30 JULY 1999 (30.07.99)
TITLE OF INVENTION PURINE METABOLISM GENES IN PLANTS		
APPLICANT(S) FOR DO/EO/US CASPAR, Timothy et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to being national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application was filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau. b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371 (c) (2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c) (3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409) 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 		
Items 13 to 18 below concern document(s) or information included :		
<ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. <input type="checkbox"/> A substitute specification. 17. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter. 18. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail. 19. <input type="checkbox"/> Other items or information: 		
<div style="border: 1px solid black; padding: 5px;"> <p>17. General Power of Attorney</p> <p>18. Express Mailing Label No.: EJ376014277US</p> </div>		

APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 10/019632		INTERNATIONAL APPLICATION NO. PCT/US00/21009		ATTORNEY'S DOCKET NUMBER BB-1386	
--	--	---	--	---	--

20. The following fees are submitted

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)) :

☒ Search Report has been prepared by the EPO or JPO \$890.00

☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) \$710.00

☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00

☐ Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00

☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) And all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). ☐ 20 ☐ 30 **\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	24 - 20 =	4 x	\$18.00	\$72.00
Independent Claims	5 - 3 =	2 x	\$84.00	\$168.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00
TOTAL OF ABOVE CALCULATIONS =				\$240.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00
SUBTOTAL =				\$240.00
Processing Fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 \$0.00				
TOTAL NATIONAL FEE =				\$1,130.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00
TOTAL FEES ENCLOSED =				\$1,130.00
				Amount to be : refunded \$
				Charged \$

☐ A check in the amount of _____ to cover the above fees enclosed.

☒ Please charge my Deposit Account No. **04-1928** in the amount of **\$1,130.00** to cover the above fees.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **04-1928** a duplicate copy of this sheet is enclosed.

NOTE : Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (CFR 1.37(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GOLIAN, Paul D.
E. I. DU PONT DE NEMOURS AND COMPANY
Legal Patent Records Center
1007 Market Street
Wilmington, Delaware 19898
United States of America

GOLIAN, Paul D.
E. I. DU PONT DE NEMOURS AND COMPANY
Legal Patent Records Center
1007 Market Street
Wilmington, Delaware 19898
United States of America

SIGNATURE _____

GOLIAN, PAUL D.

NAME _____

42,591

REGISTRATION NUMBER _____

December 19, 2001

DATE _____

TITLEPURINE METABOLISM GENES IN PLANTS

This application claims the benefit of U.S. Provisional Application No. 60/146473, filed July 30, 1999.

BACKGROUND OF THE INVENTION

Purines are components of DNA and RNA. Purine triphosphates also serve as chemical energy storage media for the cell. Regulation of purine synthesis and metabolism within the cell is critical to functions of all cells. Most mutations affecting nucleotide biosynthetic enzymes are lethal, although certain redundancy and salvage pathways may moderate the deleterious effects of some of these mutations.

Adenosine deaminase and AMP deaminase are two enzymes that convert adenosine to inosine. Mutations in these genes cause disruptions in the salvage and catabolism of adenosine and AMP. In humans these mutations may lead to death of white blood cells (lymphocytes) which in turn cause severe immunodeficiencies (Wilson et al. (1991) *Science* 252:1278-1284; Morgan and Anderson (1993) *Ann Rev Biochem* 62:191-217; Markert (1994) *Immunodeficiency* 5:141-157). Selective disruption of adenosine or AMP deaminase activities may be exploited in the identification and production of novel herbicides, insecticides, and fungicides.

SUMMARY OF THE INVENTION

The present invention concerns an isolated polynucleotide comprising: (a) a first nucleotide encoding a polypeptide that is at least 35 amino acids in length and that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 12, 14, 16, 18, 20, and 22, or (b) a second nucleotide sequence that is a complement of the first nucleotide sequence.

In a second embodiment, the isolated polynucleotide of the invention comprises a nucleotide having a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 11, 13, 15, 17, 19, and 21.

In a third embodiment, this invention concerns an isolated polynucleotide comprising at least 30 (preferably at least 40, most preferably at least 60) contiguous nucleotides derived from a member selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, or a complement thereof.

In a fourth embodiment, this invention relates to a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to at least one suitable regulatory sequence.

In a fifth embodiment, the present invention concerns an isolated host cell comprising a chimeric gene or an isolated polynucleotide of the present invention. The host cell may be

eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus, comprising an isolated polynucleotide or a chimeric gene of the present invention.

In a sixth embodiment, the invention also relates to a process for producing an isolated host cell, the process comprising either transforming or transfecting an isolated host cell with a suitable chimeric gene or isolated polynucleotide.

In a seventh embodiment, the invention concerns an isolated polypeptide that is at least 35 amino acids in length and that has at least 85% identity based on the Clustal method of alignment compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 12, 14, 16, 18, 20, and 22.

In an eighth embodiment, the invention relates to a method of selecting an isolated polynucleotide that affects the expression level or activity of an AMP or adenosine deaminase in a host cell, preferably a plant cell. According to the invention, the method comprises: (a) constructing an isolated polynucleotide or an isolated chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; (c) measuring the level of the AMP or adenosine deaminase polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and (d) selecting a suitable polynucleotide via comparing the level of the AMP or adenosine deaminase polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of the AMP or adenosine deaminase polypeptide or enzyme activity in a host cell that does not contain the isolated polynucleotide.

In a ninth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of an AMP or adenosine deaminase polypeptide, preferably a plant AMP or adenosine deaminase polypeptide, comprising: synthesizing an oligonucleotide primer comprising at least 30 (preferably at least one of 40, most preferably at least one of 60) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, or from a complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of an AMP or adenosine deaminase amino acid sequence.

In a tenth embodiment, this invention relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of an AMP or adenosine deaminase comprising: probing a cDNA or genomic library with a labeled, isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with the isolated polynucleotide; and isolating the identified DNA clone.

In an eleventh embodiment, this invention concerns a composition, such as a hybridization mixture, comprising an isolated polynucleotide of the present invention.

In a twelfth embodiment, this invention concerns a method for obtaining a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or an expression cassette comprising an isolated polynucleotide of the present invention; and (b) growing the transformed host cell, preferably a plant cell, such as a monocot or a dicot plant cell, under conditions which allow expression of the polynucleotide in an amount sufficient to complement a null mutation.

In a thirteenth embodiment, this invention relates to a method of altering the level of expression of enzymes involved in purine metabolism in a host cell comprising: (a) transforming a host cell with a chimeric gene of the present invention; and (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene alters levels of the enzymes involved in purine metabolism in the transformed host cell.

A further embodiment of the instant invention is a method for evaluating at least one compound for its ability to inhibit the activity of an enzyme involved in purine metabolism, the method comprising the steps of: (a) transforming a host cell with a chimeric gene of the invention; (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of the enzyme in the transformed host cell; (c) optionally purifying the expressed enzyme by the transformed host cell; (d) treating the enzyme with a compound to be tested; and (e) comparing the activity of the enzymes that has been treated to the activity of an untreated enzyme, thereby selecting compounds with inhibitory activity.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE LISTINGS

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listings.

Figure 1 depicts the biochemical pathway leading to purine catabolism. The steps regulated by AMP deaminase and adenosine deaminase are noted.

Figure 2 shows a comparison of the amino acid sequences of corn, rice, soybean, and wheat AMP deaminases (SEQ ID NOs:14, 16, 18, and 20, respectively) and the *Arabidopsis thaliana* AMP deaminase (SEQ ID NO:23 [gi 7484807]).

Figure 3 shows a comparison of the amino acid sequence of the soybean adenosine deaminase (SEQ ID NO:12) to the *Escherichia coli* adenosine deaminase (SEQ ID NO:24 [gi 2506342]).

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a

substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1
Enzymes Involved in Purine Metabolism

AMP Deaminase	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
Corn (<i>Zea mays</i>)	p0091.cqrav79r	1	2
Rice (<i>Oryza sativa</i>)	rsl1n.pk001.a12	3	4
Soybean (<i>Glycine max</i>)	sgs3c.pk001.m22	5	6
Wheat (<i>Triticum aestivum</i>)	wr1.pk0133.f5	7	8
Corn (<i>Zea mays</i>)	p0091.cqrav79r: fis	13	14
Rice (<i>Oryza sativa</i>)	rsl1n.pk001.a12: fis	15	16
Soybean (<i>Glycine max</i>)	sgs3c.pk001.m22: fis	17	18
Wheat (<i>Triticum aestivum</i>)	wr1.pk0133.f5: fis	19	20

Adenosine Deaminase	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
Corn (<i>Zea mays</i>)	p0005.cbmfm83r	9	10
	p0005.cbmfm83rb		
Soybean (<i>Glycine max</i>)	sls2c.pk003.f5	11	12
Soybean (<i>Glycine max</i>)	sls2c.pk003.f5	21	22

The Sequence Listing contains the standard one-letter codes for nucleotides and the three-letter codes for amino acids under the IUPAC-IUBMB (*Nucleic Acids Res.* 13:3021-3030 (1985); *Biochemical J.* 219 (No. 2):345-373 (1984)). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822. The information disclosed in SEQ ID NOs:1-12 is contained in U.S. Provisional Application No. 60/146473, filed July 30, 1999.

DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, the terms "polynucleotide," "polynucleotide sequence," "nucleic acid sequence," and "nucleic acid fragment" or "isolated nucleic acid fragment" are used interchangeably. A polynucleotide may be a RNA or DNA that may be single- or double-stranded, and may contain synthetic, non-natural or altered nucleotide bases. A DNA polynucleotide may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least one of 30 contiguous nucleotides, preferably at least one of 40 contiguous nucleotides, most preferably one of at least 60 contiguous nucleotides

derived from SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, or the complement of such sequences.

The term "isolated" polynucleotide or polypeptide refers to a molecule that is substantially free from other cellular molecules, such as other chromosomal and extrachromosomal DNA and RNA or other proteins, that normally accompany or interact with it as found in its naturally occurring environment. Isolated polynucleotides or polypeptides may be purified from a host cell in which they naturally occur. Conventional nucleic acid or protein purification methods are well known to skilled artisans. The term also embraces recombinant and chemically synthesized polynucleotides or polypeptides.

The term "recombinant" means, for example, that a nucleic acid sequence is made, or modified, by an artificial combination of two or more otherwise separated nucleic acid fragments by chemical synthesis or by genetic engineering techniques.

As used herein, "contig" refers to a contiguous nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share significant common or overlapping regions of sequence homology and can be assembled into a single contiguous nucleotide sequence, to form a "contig". Methods for comparing and

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment, or its transcripts, to alter gene expression patterns or levels, for example via gene silencing through antisense or co-suppression.

Substantially similar nucleic acid fragments may be obtained by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid fragment in a plant or plant cell.

A substantially similar nucleic acid fragment representing at least 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic acid fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using substantially similar nucleic acid fragments,

that is, nucleic acid molecules representing less than the entire coding region of a gene, or having less than 100% sequence identity with the gene to be suppressed.

Substantially similar polypeptides refer to polypeptides having one or more amino acid substitutions, additions or deletions that do not significantly affect the function of the polypeptide. One skilled in the art recognizes that conservative substitutions, whereby a residue is substituted by another with like characteristics, result in polypeptides with substantially similar functions. Typical such substitutions are among Ala, Val, Leu and Ile; between Ser and Thr; between Asp and Glu; between Asn and Gln; and between Lys and Arg; or between Phe and Tyr. Substantially similar polypeptides may have several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids substituted, deleted, or added in any combination.

Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product.

Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products.

Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least 30 (preferably at least one of 40, most preferably at least one of 60) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of an AMP or adenosine deaminase.

It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

A method of selecting an isolated polynucleotide that affects the level of expression of a gene in a virus or in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial) may comprise: constructing an isolated polynucleotide of the present invention or an chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell that expresses a native equivalent of the isolated polynucleotide; measuring the level of expression of the native gene in the host cell; and comparing the level of a polypeptide or enzyme activity in the host cell containing the

isolated polynucleotide with the level of a polypeptide or enzyme activity in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode, as determined by algorithms commonly employed by those skilled in this art. Suitable isolated polynucleotides of the present invention encode polypeptides that are at least about 70% identical, preferably at least about 80%, more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95% identical to the amino acid sequences reported herein.

Suitable nucleic acid fragments not only have the above identities but typically encode a polypeptide having at least 10, preferably 20, more preferably 30, still more preferably 50, more preferably at least 100, more preferably at least 150, still more preferably at least 200, and most preferably at least 250 amino acids.

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

Amino acid and nucleotide sequences can also be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools

that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers.

Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence.

The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of these sequences, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, it is contemplated that the instant invention encompasses complete sequences of the full-length molecules comprising the sequences as reported in the accompanying Sequence Listing, as well as substantial portions thereof.

"Codon degeneracy" refers to divergence in the genetic code permitting variations of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein.

The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to code for a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable, and within the ordinary skill of the skilled artisan, to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

"Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks, which may be chemically synthesized, using procedures known to those skilled in the art. These building blocks are ligated or annealed to form larger nucleic acid fragments that may then be enzymatically assembled to construct the entire desired nucleic acid fragment. "Chemically synthesized," as related to a nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid

fragments may be accomplished using well-established procedures. Automated chemical synthesis can be performed using one of a number of commercially available machines.

Chemical synthesis of polynucleotides allows the tailoring of a polynucleotide for optimal gene expression based on optimization of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates that successful gene expression is more likely if codon usage is biased towards those codons favored by the host.

Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

"Gene" refers to a nucleic acid fragment that code for a polypeptide molecule. A gene may also encode an RNA molecule. As generally understood, a gene includes regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence, as well as intervening sequences (introns) between individual coding segments (exons). "Native gene" refers to a gene with its native regulatory sequences.

"Chimeric gene" refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. "Indigenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign-gene" refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes may be native genes inserted into a non-native organism, or they may be chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a nucleotide sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

"Promoter" refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence that can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may

even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most
5 times are commonly referred to as "constitutive promoters." New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. **(Please use a more recent reference)** It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid
10 fragments of different lengths may have identical promoter activity.

"Translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA,
15 mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

The term "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or other
20 aspects of gene expression. The polyadenylation signal is usually characterized by effecting the addition of a polyadenylate homopolymer to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed
25 transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript. When the primary transcript has undergone posttranscriptional processing, it becomes a mature RNA.

"Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptides by the cell. "cDNA" refers to DNA that is complementary to
30 and derived from an mRNA template. The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow fragment of DNA polymerase I.

"Sense-RNA" refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide. "Antisense RNA" refers to an RNA transcript that is complementary to
all or part of a target primary transcript or mRNA and that may block the expression of a
35 target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the target gene, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence.

If the protein is to be directed to a vacuole, a vacuolar targeting signal (has not appeared previously) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Physiol.* 100:1627-1632).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, preferably resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of plant transformation methods include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) (any newer reference?) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) *Nature* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter “Maniatis”).

“PCR” or “polymerase chain reaction” is well known by those skilled in the art as a technique used for the amplification of specific DNA segments (U.S. Patent Nos. 4,683,195 and 4,800,159).

The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 30, preferably 60, still preferably 100, more preferably 150, still more

preferably 200, more preferably 250, more preferably 300, still preferably 350, still more preferably 400, still preferably 450, more preferably 500, more preferably 550, and most preferably 650 amino acids, having at least at least 30%, preferably 35%, still preferably 40%, more preferably 45%, still more preferably 50%, more preferably 55%, more preferably 60%, still preferably 65%, still more preferably 70%, still preferably 75%, more preferably 80%, more preferably 85%, and most preferably 90% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21. A particularly preferred polypeptide of the invention has an amino acid sequence of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22.

This invention provides nucleic acid fragments encoding at least a portion of several AMP or adenosine deaminases. These nucleic acids have been isolated and identified by comparison of plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art.

The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction and ligase chain reaction).

For example, genes encoding AMP or adenosine deaminases, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, an entire sequence can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

WO 01/09305

PCT/US00/21009

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. For example, one primer may be based on the sequence of the instantly disclosed polynucleotide molecules, the other primer may be based on polyA or the sequence on a vector, depending on the template used in the amplification.

Specifically, PCR may be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (Gibco BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 30 (preferably one of at least 40, most preferably one of at least 60) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, or the complement of such nucleotide sequences, may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

The present invention further relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a plant AMP or adenosine deaminases, comprising the steps of: synthesizing an first oligonucleotide primer comprising a nucleotide sequence of at least one of 30 (preferably at least one of 40, most preferably at least one of 60) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, or the complement of such nucleotide sequences; synthesizing a suitable second oligonucleotide primer, and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of an AMP or adenosine deaminase.

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing the entirety of portions of the instant amino acid sequences are synthesized. These peptides are

used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences of the synthetic peptides. These antibodies can then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

In another embodiment, this invention concerns viruses and host cells comprising either the chimeric genes of the invention or an isolated polynucleotide of the invention. Examples of host cells which can be used to practice the invention include, but are not limited to, yeast cells, bacterial cells, and plant cells. Examples of suitable viruses include (need list for written description).

As was noted above, the nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are overexpressed or their expression suppressed. This would alter the level of floral gene expression in those cells and/or flower development of transgenic plants comprising these polynucleotides.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes, and 3' non-coding sequences encoding transcription termination signals. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant isolated polynucleotide (or chimeric gene) may be constructed. The skilled artisan readily recognizes that the choice of plasmid vector is dependent upon many factors, such as when the vector for protein expression, gene over-expression or suppression, in what type of host cell the vectors are propagated, and on the method that will be used to transform host plants.

The skilled artisan is well aware of the elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene.

The skilled artisan also recognizes that different transformation events may result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and that one may have to screen multiple transformation events to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

It may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate their secretion from the cell. Accordingly, the chimeric gene of the invention

In another embodiment, the present invention concerns a polypeptide of at least 35 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in microbes, and is used to prepare antibodies to these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* or *in vitro*. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art and may be used for the instant invention. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded floral development proteins. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 7).

Additionally, the instant polypeptides can be used to design or identify herbicides that inhibit their enzyme activities. This is desirable because inhibition of the activity of one or more of the enzymes described herein could lead to inhibition of plant growth or even plant death.

All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping (*see* Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, (1996) Academic Press, pp. 319-346, and references cited therein) the genes that they compose, and used as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes.

For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map.

In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individual plants representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is used to calculate the position of the instant nucleic acid sequence in a genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in, for example, Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods for genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807).

For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a plant population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see

TABLE 2
cDNA Libraries from Corn, Rice, Soybean, and Wheat

Library	Tissue	Clone
p0097	V9 7cm whorl section + ECB1, screened 1 B73+ECB1: 7-cm whorl section Growth conditions: field plots; these plants have been infested with ECB four times prior to harvest. Growth stage: unknown; V9 or V10	p0097.cqrav79r p0097.cqrav79r:fis
rsl1n*	Rice (<i>Oryza sativa</i> , YM) 15 day old seedling normalized	rsl1n.pk001.a12 rsl1n.pk001.a12:fis
sgs3c	Soybean Seeds 25 Hours After Germination	sgs3c.pk001.m22 sgs3c.pk001.m22:fis
wr1	Wheat Root From 7 Day Old Seedling	wr1.pk0133.f5 wr1.pk0133.f5:fis
p0005	Immature Ear, two	p0005.cbmfm83r p0005.cbmfm83rb
sls2c	Soybean (<i>Glycine max</i> L., Manta) infected with <i>Sclerotinia sclerotiorum</i> mycelium.	sls2c.pk003.f5 sls2c.pk003.f5:fis

*This library was normalized essentially as described in U.S. Patent No. 5,482,845, incorporated herein by reference.

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

Full-insert sequence (FIS) data is generated utilizing a modified transposition protocol. Clones identified for FIS are recovered from archived glycerol stocks as single colonies, and plasmid DNAs are isolated via alkaline lysis. Isolated DNA templates are reacted with vector primed M13 forward and reverse oligonucleotides in a PCR-based sequencing reaction and loaded onto automated sequencers. Confirmation of clone identification is

performed by sequence alignment to the original EST sequence from which the FIS request is made.

Confirmed templates are transposed via the Primer Island transposition kit (PE Applied Biosystems, Foster City, CA) which is based upon the *Saccharomyces cerevisiae* Ty1 transposable element (Devine and Boeke (1994) *Nucleic Acids Res.* 22:3765-3772). The *in vitro* transposition system places unique binding sites randomly throughout a population of large DNA molecules. The transposed DNA is then used to transform DH10B electro-competent cells (Gibco BRL/Life Technologies, Rockville, MD) via electroporation. The transposable element contains an additional selectable marker (named DHFR; Fling and Richards (1983) *Nucleic Acids Res.* 11:5147-5158), allowing for dual selection on agar plates of only those subclones containing the integrated transposon. Multiple subclones are randomly selected from each transposition reaction, plasmid DNAs are prepared via alkaline lysis, and templates are sequenced (ABI Prism dye-terminator ReadyReaction mix) outward from the transposition event site, utilizing unique primers specific to the binding sites within the transposon.

Sequence data is collected (ABI Prism Collections) and assembled using Phred/Phrap (P. Green, University of Washington, Seattle). Phred/Phrap is a public domain software program which re-reads the ABI sequence data, re-calls the bases, assigns quality values, and writes the base calls and quality values into editable output files. The Phrap sequence assembly program uses these quality values to increase the accuracy of the assembled sequence contigs. Assemblies are viewed by the Consed sequence editor (D. Gordon, University of Washington, Seattle).

EXAMPLE 2

Identification of cDNA Clones

cDNA clones encoding AMP or adenosine deaminases were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a

WO 01/09305

PCT/US00/21009

The sequence of the entire cDNA insert in the clones listed in Table 3 was determined. The BLASTX search using the EST sequences from clones listed in Table 4 revealed similarity of the polypeptides encoded by the cDNAs to AMP deaminase from *Arabidopsis* [*Arabidopsis thaliana*](NCBI General Identifier No. gi 7484807). Shown in Table 4 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), sequences of contigs assembled from two or more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs ("Contig*"), or sequences encoding the entire protein derived from an FIS, a contig, or an FIS and PCR ("CGS"):

TABLE 4

BLAST Results for Sequences Encoding Polypeptides Homologous to AMP Deaminase

Clone	Status	BLAST pLog Score gi7484807
p0097.cqrav79r: fis	CGS	254.00
rsl1n.pk001.a12: fis	CGS	254.00
sgs3c.pk001.m22: fis	CGS	254.00
wr1.pk0133.f5: fis	FIS	254.00

Figure 2 presents an alignment of the amino acid sequences set forth in SEQ ID NOs:14, 16, 18 and 20, and the *Arabidopsis thaliana* sequence (SEQ ID NO:23). The data in Table 5 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 14, 16, 18 and 20, and the human (NCBI General Identifier No. gi 644509), yeast (NCBI General Identifier No. gi 351916), and *Arabidopsis thaliana* sequences (SEQ ID NO:23).

TABLE 8

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to Adenosine Deaminase

SEQ ID NO.	Percent Identity to		
	gi 4115949	gi 1703166	gi 2506342
10	71.7%		
12		67.6%	
22			25.8%

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of an adenosine deaminase. These sequences represent the first soybean sequence encoding adenosine deaminase known to Applicant.

EXAMPLE 5

Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli*

XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst AG, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 µL of ethanol. An aliquot (5 µL) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad

WO 01/09305

PCT/US00/21009

Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains gluphosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing gluphosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

EXAMPLE 6

Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the β subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

WO 01/09305

PCT/US00/21009

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al.(1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µl spermidine (0.1 M), and 50 µL CaCl₂ (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the

WO 01/09305

PCT/US00/21009

retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

EXAMPLE 7

Expression of Chimeric Genes in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% low melting agarose gel. Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies, Madison, WI) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs (NEB), Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene

instant polypeptides are expressed as fusion proteins, the purification protocol may include the use of an affinity resin which is specific for the fusion protein tag attached to the expressed enzyme or an affinity resin containing ligands which are specific for the enzyme. For example, the instant polypeptides may be expressed as a fusion protein coupled to the C-terminus of thioredoxin. In addition, a (His)₆ peptide may be engineered into the N-terminus of the fused thioredoxin moiety to afford additional opportunities for affinity purification. Other suitable affinity resins could be synthesized by linking the appropriate ligands to any suitable resin such as Sepharose-4B. In an alternate embodiment, a thioredoxin fusion protein may be eluted using dithiothreitol; however, elution may be accomplished using other reagents which interact to displace the thioredoxin from the resin. These reagents include β -mercaptoethanol or other reduced thiol. The eluted fusion protein may be subjected to further purification by traditional means as stated above, if desired. Proteolytic cleavage of the thioredoxin fusion protein and the enzyme may be accomplished after the fusion protein is purified or while the protein is still bound to the ThioBond™ affinity resin or other resin.

Crude, partially purified or purified enzyme, either alone or as a fusion protein, may be utilized in assays for the evaluation of compounds for their ability to inhibit enzymatic activation of the instant polypeptides disclosed herein. Assays may be conducted under well known experimental conditions which permit optimal enzymatic activity. For example, assays for AMP deaminase are presented by Meyers et al. (1989) *Biochem* 28:8734-8743. Assays for adenosine deaminase are presented by Pelcher in U.S. Patent No. 5,474,929.

What is claimed is:

1. An isolated polynucleotide:

(a) a first nucleotide sequence encoding a polypeptide of at least 35 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a member selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 12, 14, 16, 18, 20, and 22; and

(b) a second nucleotide sequence comprising a complement of the first nucleotide sequence.

2. The isolated polynucleotide of Claim 1, wherein the first nucleotide sequence comprises of a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 11, 13, 15, 17, 19, and 21.

3. The isolated polynucleotide of Claim 1 wherein the nucleotide sequence is DNA.

4. The isolated polynucleotide of Claim 1 wherein the nucleotide sequence is RNA.

5. A chimeric gene comprising the isolated polynucleotide of Claim 1 operably linked to at least one suitable regulatory sequence.

6. An isolated host cell comprising the chimeric gene of Claim 5.

7. A host cell comprising an isolated polynucleotide of Claim 1.

8. The host cell of Claim 7 wherein the host cell is selected from the group consisting of a yeast cell, a bacterial cell, and a plant cell.

9. A virus comprising the isolated polynucleotide of Claim 1.

10. A polypeptide of at least 35 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 12, 14, 16, 18, 20, and 22.

11. A method of selecting a polynucleotide molecule that affects the level of expression of an AMP or adenosine deaminase in a plant cell, the method comprising:

(a) providing a polynucleotide molecule comprising at least 30 contiguous nucleotides derived from the isolated polynucleotide of Claim 1;

(b) introducing the polynucleotide molecule into a plant cell that expresses an AMP or adenosine deaminase; and

(c) comparing the level of AMP or adenosine deaminase in the plant cell containing the isolated polynucleotide with the level of AMP or adenosine deaminase in a plant cell that does not contain the isolated polynucleotide.

12. The method of Claim 11 wherein the polynucleotide molecule is an isolated polynucleotide of Claim 1.

13. The method of Claim 11 wherein the polynucleotide molecule is an isolated polynucleotide selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 11, 13, 15, 17, 19, and 21.

14. A method of obtaining a nucleic acid fragment encoding an AMP or adenosine deaminases polypeptide, the method comprising the steps of:

(a) providing an oligonucleotide primer at least 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, or derived from a complement of the nucleotide sequences; and

(b) amplifying a nucleic acid sequence using the oligonucleotide primer.

15. A method of obtaining a nucleic acid fragment encoding an AMP or adenosine deaminases polypeptide, the method comprising the steps of:

(a) probing a cDNA or genomic library with a nucleotide probe comprising at least 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, or derived from a complement of such nucleotide sequences;

(b) identifying a clone that hybridizes with the probe; and

(c) isolating the clone.

16. A composition comprising the isolated polynucleotide of Claim 1.

17. A composition comprising the isolated polypeptide of Claim 10.

18. A transformed plant cell comprising the chimeric gene of Claim 5.

19. A method for producing a transformed cell comprising transforming a cell with the chimeric gene of Claim 5.

20. The method of Claim 19 wherein the cell is a plant cell.

21. The method of Claim 20 wherein the plant cell is a monocot plant cell.

22. The method of Claim 20 wherein the plant cell is a dicot plant.

23. A method of altering the expression level an AMP deaminase or an adenosine deaminase in a host cell comprising:

(a) providing a transformed host cell comprising the chimeric gene of Claim 5; and

(b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene

wherein expression of the chimeric gene alters the expression levels of the AMP deaminase or the adenosine deaminase in the transformed host cell.

24. A method for evaluating a compound for its ability to inhibit the activity of an AMP deaminase or an adenosine deaminase, the method comprising:

WO 01/09305

PCT/US00/21009

- (a) providing a transformed host cell with a chimeric gene comprising a nucleic acid fragment encoding an AMP deaminase or an adenosine deaminase;
- (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene, wherein the expression produces an AMP deaminase or an adenosine deaminase;
- (c) optionally purifying the AMP deaminase or adenosine deaminase produced;
- (d) treating the AMP deaminase or adenosine deaminase polypeptide with a compound to be tested; and
- (e) determining the inhibitory effect of the compound tested by comparing the activity of the AMP deaminase or adenosine deaminase polypeptide that has been treated to the activity of an untreated enzyme.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)


PCT

(10) International Publication Number
WO 01/09305 A2

- (51) International Patent Classification⁷: C12N 15/00
- (21) International Application Number: PCT/US00/21009
- (22) International Filing Date: 28 July 2000 (28.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/146,473 30 July 1999 (30.07.1999) US
- (71) Applicants (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 7100 N.W. 62nd Avenue, Johnston, IA 50131 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): CASPAR, Timothy [US/US]; 2927 Barley Mill Road, Yorklyn, Wilmington, DE 19736 (US). FALCO, Saverio, Carl [US/US]; 1902 Miller Road, Arden, DE 19810 (US). SAKAI, Hajime [DE/US]; 105 Banbury Drive, Wilmington, DE 19803 (US). WENG, Zude [CN/US]; Apartment 301, 495 Leslie Court, Des Plaines, IL 60016 (US). HU, Xu [CA/US]; 4700 103rd Street, Urbandale, IA 50322 (US).
- (74) Agent: LI, Kening; E.I. Du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO,

[Continued on next page]

(54) Title: PURINE METABOLISM GENES IN PLANTS



(57) Abstract: This invention relates to an isolated nucleic acid fragment encoding an AMP deaminase or adenosine deaminase, a transformed host cell comprising the nucleic acid fragment, and a transgenic plant comprising the nucleic acid fragment. The invention also relates to the construction of a chimeric gene encoding all or a substantial portion of an AMP or adenosine deaminase, and a chimeric gene comprising the isolated fragment in sense or antisense orientation. This invention further relates to a method for altering expression level of AMP deaminase or adenosine deaminase in a transformed host cell, and a method for evaluating a compound that affects the activity of an AMP deaminase or an adenosine deaminase.



RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
US, UZ, VN, YU, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/09305

PCT/US00/21009



10/019633

FIGURE 2

Comparison of AMP Deaminase Polypeptides From Corn, Rice, Soybean, and Wheat (SEQ ID NOs:14, 16, 18, and 20) and *Arabidopsis thaliana*

```

SEQ ID NO:14      -----EIPTADEIE
SEQ ID NO:16      MPKTPVSLITKWD--IGSDPLPGKASQNGDTKVPSTNIRSQSATGSLHCAQHPVAADILRKEPEHEHETSRINITAVETSPSPDEIE
SEQ ID NO:18      LDTTYLHANGTGGPEGKIPPEPLPNHVNANGEQMAITPS--MIRSHSVSGDLHGVPDPIAADILRKEPEHEHETTRLRITPLEAPSPDEIE
SEQ ID NO:20      -----
gi 7484807        M-----ICL-----EVPTSDEVE

SEQ ID NO:14      VFKILXKCIELRDSYLFREEVAPWEKEVINDPCTPKPNPNFTYVPEPKSEHVFTQVDGVIHVYADKDCSTESIYPVADATTTFTDLHYIL
SEQ ID NO:16      AYKVLQKCLELRREKYMFRREVAPWEKEIITDPSTPKPNPNFYEEQQTKEHHFEMVDGVIHVYPNKDAKERIYPVADATTTFTDMHYIL
SEQ ID NO:18      AYVVLQECLEMRKRYVFRFAVAPWDKEVISDPSTPKPNPDPLYIPEGNSDHYFEMQDGVIRVYPDRDAKEELFPVADATTTFTDLHLL
SEQ ID NO:20      -----R-C-----
gi 7484807        AYKCLQECLELRKRYVFOETVAPWEKEVISDPSTPKPNTEPEFAHYPOGKSDHCFEMQDGVVHVFAKDAKEDLFPVADATATFTDLHHVL

SEQ ID NO:14      RVTAAGNTRTVCHNRLNLEHKKFHLMLNADREFLAQKTAAPHRDFYNVRKVDTHVHHSACMNQKHLLRFIKSKLRKEPDEVVIFRDGTY
SEQ ID NO:16      RVLAAGDIRTVCYKRLNLEQKFNHLMVNADRELLAQKAAPHRDFYNVRKVDTHVHHSACMNQKHLLRFIKSKLRKEPDEVVIFRDGTY
SEQ ID NO:18      RVIAAGNIRTLCHHRLNLEQKFNHLMLNADREFLAQKSAAPHRDFYNVRKVDTHVHHSACMNQKHLLRFIKSKLRKEPDEVVIFRDGTY
SEQ ID NO:20      -----KF-----
gi 7484807        KVIAAGNIRTLCHHRLNLEQKFNHLMLNADKEFLAQKSAAPHRDFYNVRKVDTHVHHSACMNQKHLLRFIKSKLRKEPDEVVIFRDGTY

SEQ ID NO:14      MTLKEVFESLDLTGYDLNVDDLVDHADKSTFHRFDKFNLYNPNPCGQSRRLREIFLKQDNLIQGRFLAELTKQVFSDSLASKYQMAEYRISI
SEQ ID NO:16      LTLKEVFESLDLTGYDLNVDDLVDHADKSTFHRFDKFNLYNPNPCGQSRRLREIFLKQDNLIQGRFLAELTKQVFSDSLASKYQMAEYRISI
SEQ ID NO:18      LTLEEVEKSLDLSGYDLNVDDLVDHADKSTFHRFDKFNLYNPNPCGQSRRLREIFLKQDNLIQGRFLGELTKQVFSDLAASKYQMAEYRISI
SEQ ID NO:20      -----FSDLNASKYQMAEYRISI
gi 7484807        LTLREVFEFSLDLTGYDLNVDDLVDHADKSTFHRFDKFNLYNPNPCGQSRRLREIFLKQDNLIQGRFLGELTKQVFSDLAASKYQMAEYRISI

SEQ ID NO:14      YGRKQSEWDQLASWIYNNELHSGNVVWLVIQIPRLYNYVKEMGIVTSFQNLLDNIFVPLFEVTIDPASHPOLHVFLKQVVGGLDLVDDESKP
SEQ ID NO:16      YGRKQSEWDQMASWIYNNELYSENVVWLVIQIPRIYNYVREMGTINSFQNLLDNIFLPLFEVTIDPASHPOLHVFLKQVVGGLDLVDDESKP
SEQ ID NO:18      YGRKQSEWDQLASWIYNNELYSENVVWLVIQIPRLYNYVKEMGIVTSFQNLLDNIFIPLEFVTVPDASHPOLHVFLKQVVGGLDLVDDESKP
SEQ ID NO:20      YGRKQSEWDQLASWIYNNELYSENVVWLVIQIPRLYNYVQMGIVTSFQNLLDNIFLPLFEVTIDPASHPOLHVFLKQVVGGLDLVDDESKP
gi 7484807        YGRKQSEWDQLASWIYNNELYSENVVWLVIQIPRLYNYKMGIVTSFQNLLDNIFIPLEFVTVPDASHPOLHVFLKQVVGGLDLVDDESKP

```

10/019633

FIGURE 2 (continued)

SEQ ID NO:14	ERRPTKHMPTPEQWNTNVNPAFSYAYCYANLFTLNKLRESKGMTTIKFRPHAGEAGDVHDLAATFLLCNISHGINLRKSPVLQYLYY
SEQ ID NO:16	ERRPTKHMPTPEQWNTNVNPAFSYAYCYANLFTLNKLRESKGMTTIKFRPHAGEAGDVHDLAATFLTSNIAHGVNLRKSPVLQYLYY
SEQ ID NO:18	ERRPTKHMPTPEQWNTNVNPAFSYAYCYANLFTLNKLRESKGMTTIKFRPHAGEAGDVHDLAATFLTAHNIAGINLRKSPVLQYLYY
SEQ ID NO:20	ERRPTKHMPTPEQWNTNVNPAFSYAYCYANLFTLNKLRESKGMTTIKFRPHAGEAGDVHDLAATFLLCNISHGINLRKSPVLQYLYY
gi 7484807	ERRPTKHMPTPEQWNTNVNPAFSYAYCYANLFTLNKLRESKGMTTIKFRPHAGEAGDVHDLAATFLTCHSIAHGINLRKSPVLQYLYY
SEQ ID NO:14	LGQIGLAMSPLSNNSLFLDYHRNPFPTFFQRLNVSLSLTDPLQIHLTKPLVEEYSIAASLWKLSSCDLCEIARNSVYQSGFSHALKAH
SEQ ID NO:16	LAQIGLAMSPLSNNSLFLDYHRNPFPTFFQRLNVSLSLTDPLQIHLTKPLVEEYSIAASLWKLSSCDLCEIARNSVYQSGFSHRLKSH
SEQ ID NO:18	LAQIGLAMSPLSNNSLFLDYHRNPFPTFFQRLNVSLSLTDPLQIHLTKPLVEEYSIAASLWKLSSCDLCEIARNSVYQSGFSHRLKSH
SEQ ID NO:20	LAQIGLAMSPLSNNSLFLDYHRNPFPTFFQRLNVSLSLTDPLQIHLTKPLVEEYSIAASLWKLSSCDLCEIARNSVYQSGFSHALKAH
gi 7484807	LAQIGLAMSPLSNNSLFLDYHRNPFPTFFQRLNVSLSLTDPLQIHLTKPLVEEYSIAASLWKLSSCDLCEIARNSVYQSGFSHALKSH
SEQ ID NO:14	WIGKNYFKRGPGAGNDIHRNTNVPHIRVQFREMWRNEMKLVYSDNEILIPDEL
SEQ ID NO:16	WIGKNYFKRGPGAGNDIHRNTNVPHIRVQFREMWRNEMKLVYSDNEILIPDEL
SEQ ID NO:18	WIGKNYFKRGPGAGNDIHRNTNVPHIRVQFREMWRNEMKLVYSDNEILIPDEL
SEQ ID NO:20	WIGKNYFKRGPGAGNDIHRNTNVPHIRVQFREMWRNEMKLVYSDNEILIPDEL
gi 7484807	WIGKNYFKRGPGAGNDIHRNTNVPHIRVQFREMWRNEMKLVYSDNEILIPDEL

FIGURE 3
Comparison of Adenosine Deaminase Polypeptides From Soybean (SEQ ID NO:22) and *E. coli*

SEQ ID NO:22 gi 2506342	MCGENMKQFLKELPKCEHHIHIEGSLSPALLFELAKTNNIALPDSAADASFKEPQELSRYERFTSLNDFLHYIYIGMSVLINPADYESL MIDT-----TLPITDIHRHLDGNIRPQTILELGRQYNISLPAQSLETLIPHVQVIANE-----PDLVSFLTCLKLDWGVKVLASLDACRRV
SEQ ID NO:22 gi 2506342	AYEYLTKANRDGVVHAEIFFDPQ-AHTERGIAYNVTVVEGLSAGLKRAEKDFGITSKLILCFLRHLSAEDAKTTTQEA VSLGHFSGTVA AFENIEDAARHGLHYVELRFSPCYMAMAHQLPVAGVVEAVIDGVREGCRTFGVQAKLIGIMSRFTGEEAACQOELEA--FLAH--RDQITA
SEQ ID NO:22 gi 2506342	IGLDSSEVGFPEIFREIYESAETKGIHRTAHAGEEGDTSYISRALDICKVERIDHGIRLAEDENLLKRVAEQGTMLTVCPLSNVRLRCV LDLAGDELGFGSLFLSHFNARDAGWHITVHAGEAAGPESINQAIRELGAERIGHGVKAIEDRALMDFLAEQQIGIESCLTSNIQTSTV
SEQ ID NO:22 gi 2506342	ENVGQLPIRKFLDGGIKFSINSDDPAYFGGYILDNYLAVQEAFGNLKWKYIATSAIEGWCDDERKAVLLSKVDACAKKYEALL AELAAHPLKTFLEHGIRASINTDDPGVQGVDTIHEYTVAAPAGLSREQIROAQINGLEMAFLSAEEKRALREKVAA-----K

WO 01/09305

SEQUENCE LISTING

<110> E.I. du Pont de Nemours and Company

<120> PURINE METABOLISM GENES IN PLANTS

<130> BB-1386-P1

<140>

<141>

<150> BB1386 US PRV

<151> 1999-07-30

<160> 24

<170> Microsoft Office 97

<210> 1

<211> 1910

<212> DNA

<213> Zea mays

<400> 1

```

ccacgcgtcc ggggtgctcc atgggagaag gaggtcataa atgacccctg tactccaaaa 60
cctaacccca acccggttcac ttatgtgcct gaaccaaaagt cagagcatgt tttccaaaact 120
gttgatggcg ttatccatgt ttatgcggat aaagattgta cggagagcat ttatcctgtg 180
gctgatgcta caaccttctt cactgacttg cattatattc tccgagtaac ggctgcaggg 240
aacacaagaa ctgtctgcca taatcggtta aatcttcttg agcataagtt taaattccat 300
ctgatgttaa atgcggatag ggaatttctt gcccagaaga ctgcccaca tctgtgatttt 360
tacaatgtca ggaaggttga cactcatgtt catcattcag catgcatgaa tcaaaaacat 420
ctgttgaggt tcataaaatc caaactaaga aaagaacctg atgaggtggg cattttcaga 480
gatgggtactt atatgacttt aaaagaggtt tttgagagct tggacttaac tgggtatgat 540
ctgaatgttg atttgctaga tgtccatgca gacaaaagca catttcatcg ttttgacaaa 600
ttcaatctaa aatacaatcc atgtggccaa agtaggtcca gagaaatttt cctcaaacia 660
gataatctta ttcaggccg ttttcttgct gagttgacaa agcaagtttt ctctgacctt 720
tctgctagca aatatcagat ggcagaatat aggtattcaa tctacggaag gaaacagagt 780
gaatgggacc aacttgcaag ttggatagtg aacaatgaat tgcacagtgg aaatgttgct 840
tggctggttc agattccacg cttatataat gtgtacaagg aaatgggtat cgttacatca 900
ttccaaaatc ttcttgacaa cattttcgtt cctctttttg aggttactat tgatccagct 960
tcacacccac agtcccatgt ctctctgaag caggttgtag ggttgacctt ggttgatgat 1020
gaaagtaaac cagaaaggcg tccaacaaag cacatgcca cacctgaaca gtggaccaat 1080
gtgttcaacc ctgcattttc atattatgct tactactgct atgctaactt attcacccta 1140
aacaagctgc gtgagtcaaa gggaatgacc actatcaaat tccgtccaca tgctggagag 1200
gctggagatg ttgatcactt ggcagcgaca tttcttctct gtcacaacat atcacatgga 1260
attaatctaa ggaagtctcc tgtgtctcag tacttgact atcttggtca gattggtctg 1320
gcgatgtccc cattgagcaa caactcctta tttcttgact atcatcgcaa cccttttcca 1380
acgttcttcc aacgaggtct gaatgtctca ttatctacgg atgacccctt gcaaattcac 1440
ctgacaaaag aaccattggt ggaagaatac agcattgctg ctctgctgtg gaagctcagt 1500
tcttgtgatt tatgcgaaat tgcgaggaa cctgtttacc aatctgggtt ttcacatgct 1560
ctcaaggcgc actggattgg taagaactac ttcaaaagag gacctgctgg aaatgatatt 1620
cacagaacca atgtaccgca catcagggtt caatttagag agatgatctg gagaaatgaa 1680
atgaaactag tgtactctga caatgagatc ttaataccag acgagctgga cctgtaagat 1740
gtccagcctc gtgtatacca gacgagttgc gttgtagctg ctatgggaat tatacttcat 1800
gttttggtat gctttcctta tctatggcaa attcaacttc gaacttcaaa aaaaaaaaaa 1860
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1910

```

<210> 2

<211> 578

<212> PRT

<213> Zea mays

<400> 2

Pro Arg Val Arg Val Ala Pro Trp Glu Lys Glu Val Ile Asn Asp Pro
 1 5 10 15

Cys Thr Pro Lys Pro Asn Pro Asn Pro Phe Thr Tyr Val Pro Glu Pro
 20 25 30

Lys Ser Glu His Val Phe Gln Thr Val Asp Gly Val Ile His Val Tyr
 35 40 45

Ala Asp Lys Asp Cys Thr Glu Ser Ile Tyr Pro Val Ala Asp Ala Thr
 50 55 60

Thr Phe Phe Thr Asp Leu His Tyr Ile Leu Arg Val Thr Ala Ala Gly
 65 70 75 80

Asn Thr Arg Thr Val Cys His Asn Arg Leu Asn Leu Leu Glu His Lys
 85 90 95

Phe Lys Phe His Leu Met Leu Asn Ala Asp Arg Glu Phe Leu Ala Gln
 100 105 110

Lys Thr Ala Pro His Arg Asp Phe Tyr Asn Val Arg Lys Val Asp Thr
 115 120 125

His Val His His Ser Ala Cys Met Asn Gln Lys His Leu Leu Arg Phe
 130 135 140

Ile Lys Ser Lys Leu Arg Lys Glu Pro Asp Glu Val Val Ile Phe Arg
 145 150 155 160

Asp Gly Thr Tyr Met Thr Leu Lys Glu Val Phe Glu Ser Leu Asp Leu
 165 170 175

Thr Gly Tyr Asp Leu Asn Val Asp Leu Leu Asp Val His Ala Asp Lys
 180 185 190

Ser Thr Phe His Arg Phe Asp Lys Phe Asn Leu Lys Tyr Asn Pro Cys
 195 200 205

Gly Gln Ser Arg Leu Arg Glu Ile Phe Leu Lys Gln Asp Asn Leu Ile
 210 215 220

Gln Gly Arg Phe Leu Ala Glu Leu Thr Lys Gln Val Phe Ser Asp Leu
 225 230 235 240

Ser Ala Ser Lys Tyr Gln Met Ala Glu Tyr Arg Ile Ser Ile Tyr Gly
 245 250 255

Arg Lys Gln Ser Glu Trp Asp Gln Leu Ala Ser Trp Ile Val Asn Asn
 260 265 270

Glu Leu His Ser Gly Asn Val Val Trp Leu Val Gln Ile Pro Arg Leu
 275 280 285

Tyr Asn Val Tyr Lys Glu Met Gly Ile Val Thr Ser Phe Gln Asn Leu
 290 295 300

Leu Asp Asn Ile Phe Val Pro Leu Phe Glu Val Thr Ile Asp Pro Ala
 305 310 315 320

Ser His Pro Gln Leu His Val Phe Leu Lys Gln Val Val Gly Leu Asp
 325 330 335
 Leu Val Asp Asp Glu Ser Lys Pro Glu Arg Arg Pro Thr Lys His Met
 340 345 350
 Pro Thr Pro Glu Gln Trp Thr Asn Val Phe Asn Pro Ala Phe Ser Tyr
 355 360 365
 Tyr Ala Tyr Tyr Cys Tyr Ala Asn Leu Phe Thr Leu Asn Lys Leu Arg
 370 375 380
 Glu Ser Lys Gly Met Thr Thr Ile Lys Phe Arg Pro His Ala Gly Glu
 385 390 395 400
 Ala Gly Asp Val Asp His Leu Ala Ala Thr Phe Leu Leu Cys His Asn
 405 410 415
 Ile Ser His Gly Ile Asn Leu Arg Lys Ser Pro Val Leu Gln Tyr Leu
 420 425 430
 Tyr Tyr Leu Gly Gln Ile Gly Leu Ala Met Ser Pro Leu Ser Asn Asn
 435 440 445
 Ser Leu Phe Leu Asp Tyr His Arg Asn Pro Phe Pro Thr Phe Phe Gln
 450 455 460
 Arg Gly Leu Asn Val Ser Leu Ser Thr Asp Asp Pro Leu Gln Ile His
 465 470 475 480
 Leu Thr Lys Glu Pro Leu Val Glu Glu Tyr Ser Ile Ala Ala Ser Leu
 485 490 495
 Trp Lys Leu Ser Ser Cys Asp Leu Cys Glu Ile Ala Arg Asn Ser Val
 500 505 510
 Tyr Gln Ser Gly Phe Ser His Ala Leu Lys Ala His Trp Ile Gly Lys
 515 520 525
 Asn Tyr Phe Lys Arg Gly Pro Ala Gly Asn Asp Ile His Arg Thr Asn
 530 535 540
 Val Pro His Ile Arg Val Gln Phe Arg Glu Met Ile Trp Arg Asn Glu
 545 550 555 560
 Met Lys Leu Val Tyr Ser Asp Asn Glu Ile Leu Ile Pro Asp Glu Leu
 565 570 575
 Asp Leu

<210> 3
 <211> 1816
 <212> DNA
 <213> Oryza sativa

<400> 3
 gcacgagtaa acgttttaaat cttctagaac agaaattcaa tcttcatttg atgggtcaatg 60
 ccgatagaga actacttgct cagaaagctg caccctatcg ggacttctac aatgtcagga 120

```

aggttgatac tcatgttcat cactctgcat gcatgaatca gaagcatctg ttgagattta 180
tcaagtccaa gttgaggaaa gaacctgacg aggttgatgat ttttagagat ggtacctatt 240
tgactcttaa ggaggttttt gagagtttgg acttgactgg ttatgacctc aatgttgatc 300
tcttagatgt gcatgccgat aaaagtacat tccatcgctt tgacaagttc aatttgaagt 360
ataatccttg tggccaatcc cggctgaggg agatctttct taaacaggac aaccttattc 420
aaggccgatt tcttgctgaa ttgacaaaag aagtattttc tgatcttgaa gcaagtaaat 480
atcagatggc tgagtataga atatctatct atgggagaaa gaaaagtgag tgggacaga 540
tggcaagctg gatagtgaat aatgaattgt acagcgagaa tgttgtttgg ttaattcaga 600
ttcctcggat atacaatgta tacagggaga tgggaacaat caattctttc cagaacctcc 660
ttgacaatat ttttctgcct ctttttgaag taactgttga tcctgcttca catcctcagc 720
tccatgtttt cttgcaacag gtcgttgggc tggatttagt ggatgatgaa agcaaaccag 780
agagacgccc aacaaaacac atgcctacac ctgagcaatg gactaatgtt ttcaatccag 840
catagtcata ttatgtgtac tattgttatg ctaacttgta cacgctgaac aagcttcgtg 900
agtccaaggg tatgacaaca atcaaaactc gtccacactg tggggaggct ggagatattg 960
atcatcttgc tgcagcattt cttactttct ataattattg tcacgggggtt aatttaaaga 1020
agtcccctgt cctccagtat ctgtattacc tagctcagat tggctcttgc atgtctcctt 1080
tgagcaacaa ctcaatgttt attgattatc accgaaacct tttcccaaca ttttctctaa 1140
gaggccttaa cgtttctcta tcaaccgatg accctttgca aattcacctg acaaaagaac 1200
ctttggttga agaatatagc atcgctgctt cgctgtggaa gctaagttca tgcgacctat 1260
gtgaaattgc taggaattct gtgtaccagt ctggtttctc tcataggctc aagtcacact 1320
ggattgggag aaactactac aaaagaggtc atgattggaa tgacattcac cagacaaatg 1380
ttcctcacat caggattgaa ttccgacaca ctatttggaa agaagaaatg gagctaatac 1440
atctgaggaa tgttgatata ccggaagaaa ttgatagggt aagacctggc aagaattttg 1500
caaaccctga agttacttgg ttgttgatga tggctcctgga aggcacccca tcttctacc 1560
ataaactttc cagggtacaac caagaccgtg cggtttctac ttgcttgagg aagggaggag 1620
aaagggatct aggatgattc tacttttctg tgaatctccg tagcgtgttg cgttccctag 1680
tagtaggatt ttgataaaaag aaattatgtt aggactgagg ccgtaccata aaataagaaa 1740
gatttgagtc atggaatact ggaagtttaa acataaaaaa aaaaaaaaaa aaaaaaaaaa 1800
aaaaaaaaaa aaaaaa 1816

```

<210> 4
 <211> 492
 <212> PRT
 <213> Oryza sativa

<400> 4
 Thr Ser Lys Arg Leu Asn Leu Leu Glu Gln Lys Phe Asn Leu His Leu
 1 5 10 15
 Met Val Asn Ala Asp Arg Glu Leu Leu Ala Gln Lys Ala Ala Pro His
 20 25 30
 Arg Asp Phe Tyr Asn Val Arg Lys Val Asp Thr His Val His His Ser
 35 40 45
 Ala Cys Met Asn Gln Lys His Leu Leu Arg Phe Ile Lys Ser Lys Leu
 50 55 60
 Arg Lys Glu Pro Asp Glu Val Val Ile Phe Arg Asp Gly Thr Tyr Leu
 65 70 75 80
 Thr Leu Lys Glu Val Phe Glu Ser Leu Asp Leu Thr Gly Tyr Asp Leu
 85 90 95
 Asn Val Asp Leu Leu Asp Val His Ala Asp Lys Ser Thr Phe His Arg
 100 105 110
 Phe Asp Lys Phe Asn Leu Lys Tyr Asn Pro Cys Gly Gln Ser Arg Leu
 115 120 125

WO 01/09305

PCT/US00/21009

Arg Glu Ile Phe Leu Lys Gln Asp Asn Leu Ile Gln Gly Arg Phe Leu
130 135 140

Ala Glu Leu Thr Lys Glu Val Phe Ser Asp Leu Glu Ala Ser Lys Tyr
145 150 155 160

Gln Met Ala Glu Tyr Arg Ile Ser Ile Tyr Gly Arg Lys Lys Ser Glu
165 170 175

Trp Asp Gln Met Ala Ser Trp Ile Val Asn Asn Glu Leu Tyr Ser Glu
180 185 190

Asn Val Val Trp Leu Ile Gln Ile Pro Arg Ile Tyr Asn Val Tyr Arg
195 200 205

Glu Met Gly Thr Ile Asn Ser Phe Gln Asn Leu Leu Asp Asn Ile Phe
210 215 220

Leu Pro Leu Phe Glu Val Thr Val Asp Pro Ala Ser His Pro Gln Leu
225 230 235 240

His Val Phe Leu Gln Gln Val Val Gly Leu Asp Leu Val Asp Asp Glu
245 250 255

Ser Lys Pro Glu Arg Arg Pro Thr Lys His Met Pro Thr Pro Glu Gln
260 265 270

Trp Thr Asn Val Phe Asn Pro Ala Tyr Ala Tyr Tyr Val Tyr Tyr Cys
275 280 285

Tyr Ala Asn Leu Tyr Thr Leu Asn Lys Leu Arg Glu Ser Lys Gly Met
290 295 300

Thr Thr Ile Lys Leu Arg Pro His Cys Gly Glu Ala Gly Asp Ile Asp
305 310 315 320

His Leu Ala Ala Ala Phe Leu Thr Ser His Asn Ile Ala His Gly Val
325 330 335

Asn Leu Lys Lys Ser Pro Val Leu Gln Tyr Leu Tyr Tyr Leu Ala Gln
340 345 350

Ile Gly Leu Ala Met Ser Pro Leu Ser Asn Asn Ser Met Phe Ile Asp
355 360 365

Tyr His Arg Asn Pro Phe Pro Thr Phe Phe Leu Arg Gly Leu Asn Val
370 375 380

Ser Leu Ser Thr Asp Asp Pro Leu Gln Ile His Leu Thr Lys Glu Pro
385 390 395 400

Leu Val Glu Glu Tyr Ser Ile Ala Ala Ser Leu Trp Lys Leu Ser Ser
405 410 415

Cys Asp Leu Cys Glu Ile Ala Arg Asn Ser Val Tyr Gln Ser Gly Phe
420 425 430

Ser His Arg Leu Lys Ser His Trp Ile Gly Arg Asn Tyr Tyr Lys Arg
435 440 445

Gly His Asp Gly Asn Asp Ile His Gln Thr Asn Val Pro His Ile Arg
 450 455 460

Ile Glu Phe Arg His Thr Ile Trp Lys Glu Glu Met Glu Leu Ile His
 465 470 475 480

Leu Arg Asn Val Asp Ile Pro Glu Glu Ile Asp Arg
 485 490

<210> 5
 <211> 551
 <212> DNA
 <213> Glycine max

<220>
 <221> unsure
 <222> (290)

<220>
 <221> unsure
 <222> (294)

<220>
 <221> unsure
 <222> (317)

<220>
 <221> unsure
 <222> (396)

<220>
 <221> unsure
 <222> (411)

<220>
 <221> unsure
 <222> (455)

<220>
 <221> unsure
 <222> (510)

<220>
 <221> unsure
 <222> (513)

<220>
 <221> unsure
 <222> (540)

<400> 5
 attcaatctt catttgatgc taaatgcgga tagagaatctt cttgctcaga agagtgtctcc 60
 acatcgagac ttctataatg ttagaaaagt tgatactcat gtccaccact cagcatgcat 120
 gaatcagaaa catcttttaa ggttcataaa gtcaaagctg agaaaagagc ctgatgaggt 180
 tgtaatatctt cgagatggga catatctaac gttggaagag gttttcaaga gtttagatctt 240
 gtctgggata tgacctcaat gttgacctt tgggacgttc acgcaagacn agantacttt 300
 catccgcttt ggataanttc aatctttaa acaacccttg cgggtcaaagt aagccaaggg 360
 agatatctct taagcaagga tatctcatca aggccttcc ttggtgagtt nactaacaag 420
 tgtttcaaat cttgctgccca ttaatatcaa gaggntgaat atagaatata atatagggtta 480

WO 01/09305

PCT/US00/21009

gggagcaaat gagtgggaca actacccttn gtngtggata agattgtcag cgagaagtcn 540
ttgggtgatc a 551

<210> 6
<211> 82
<212> PRT
<213> Glycine max

<400> 6
Phe Asn Leu His Leu Met Leu Asn Ala Asp Arg Glu Phe Leu Ala Gln
1 5 10 15

Lys Ser Ala Pro His Arg Asp Phe Tyr Asn Val Arg Lys Val Asp Thr
20 25 30

His Val His His Ser Ala Cys Met Asn Gln Lys His Leu Arg Phe
35 40 45

Ile Lys Ser Lys Leu Arg Lys Glu Pro Asp Glu Val Val Ile Phe Arg
50 55 60

Asp Gly Thr Tyr Leu Thr Leu Glu Glu Val Phe Lys Ser Leu Asp Leu
65 70 75 80

Ser Gly

<210> 7
<211> 662
<212> DNA
<213> Triticum aestivum

<220>
<221> unsure
<222> (230)

<220>
<221> unsure
<222> (377)

<220>
<221> unsure
<222> (389)

<220>
<221> unsure
<222> (439)

<220>
<221> unsure
<222> (447)

<220>
<221> unsure
<222> (465)

<220>
<221> unsure
<222> (467)

<220>
<221> unsure
<222> (474)

<220>
<221> unsure
<222> (482)

<220>
<221> unsure
<222> (492)

<220>
<221> unsure
<222> (497)

<220>
<221> unsure
<222> (509)

<220>
<221> unsure
<222> (521)

<220>
<221> unsure
<222> (530)

<220>
<221> unsure
<222> (538)

<220>
<221> unsure
<222> (568)..(569)

<220>
<221> unsure
<222> (579)

<220>
<221> unsure
<222> (587)

<220>
<221> unsure
<222> (600)..(601)

<220>
<221> unsure
<222> (616)

<220>
<221> unsure
<222> (620)

<220>
<221> unsure
<222> (632)

<220>

<221> unsure

<222> (638)

<220>

<221> unsure

<222> (641)

<220>

<221> unsure

<222> (661)

<400> 7

```

cttaaacagg acaatcttat tcaaggacga tttcttgctg agctgacgat gcaagttttt 60
ttctgacctt aatgcaagca agtatcagat ggctgaatat aggatttcaa tctatgggag 120
gaagcaaagt gagggggacc aacttgcgag ttggatagta aacaatgaat tgtacagtga 180
aaatgttgtt tgggttgatc aagatccacg cttatataac gtgtaccaan caaatgggga 240
ttgttacatc atttcaaaaa ctctcttgga caacatttcc ctctctctgt ttggagggtta 300
ctatgatcca gttctcacc cgcacttcat gtcttcccta aagcaggcct aggggttagat 360
ttggttgatg atgaaantaa cctgaaagng tccaactaac acatgcctac acctgaaaga 420
aggacgatgt ctcaaaccng atttcanaat aagcatacta cggcnancta cttnttcaca 480
cngacaacgc gnagcanagg gagatacanc aaatccgtca natccgtgan gcggaacntg 540
atacttgaac aacattctct tgccatannc catgatcant taggagnccc gtctcaaacn 600
ncaccttgca attgcngaen tcccccaaaa ancctttntg ncacgacctt tcagtttaag 660
ng 662

```

<210> 8

<211> 107

<212> PRT

<213> Triticum aestivum

<220>

<221> UNSURE

<222> (56)

<220>

<221> UNSURE

<222> (81)

<220>

<221> UNSURE

<222> (105)

<400> 8

```

Asp Leu Asn Ala Ser Lys Tyr Gln Met Ala Glu Tyr Arg Ile Ser Ile
 1           5           10          15
Tyr Gly Arg Lys Gln Ser Glu Trp Asp Gln Leu Ala Ser Trp Ile Val
          20          25          30
Asn Asn Glu Leu Tyr Ser Glu Asn Val Val Trp Val Asp Gln Asp Pro
          35          40          45
Arg Leu Tyr Asn Val Tyr Gln Xaa Lys Trp Gly Leu Leu His His Phe
          50          55          60
Lys Asn Phe Leu Gly Gln His Phe Pro Pro Pro Val Trp Arg Leu Leu
          65          70          75          80

```


WO 01/09305

PCT/US00/21009

Xaa Ser Ser Ser His Pro Ala Leu His Val Phe Pro Lys Ala Gly Leu
85 90 95

Gly Leu Asp Leu Val Asp Asp Glu Xaa Asn Leu
100 105

<210> 9
<211> 673
<212> DNA
<213> Zea mays

<220>
<221> unsure
<222> (412)

<220>
<221> unsure
<222> (425)

<220>
<221> unsure
<222> (433)

<220>
<221> unsure
<222> (449)

<220>
<221> unsure
<222> (471)

<220>
<221> unsure
<222> (502)

<220>
<221> unsure
<222> (518)

<220>
<221> unsure
<222> (526)

<220>
<221> unsure
<222> (538)

<220>
<221> unsure
<222> (543)

<220>
<221> unsure
<222> (546)

<220>
<221> unsure
<222> (560)

WO 01/09305

PCT/US00/21009

<220>
 <221> unsure
 <222> (563)

<220>
 <221> unsure
 <222> (568)

<220>
 <221> unsure
 <222> (570)

<220>
 <221> unsure
 <222> (572)

<220>
 <221> unsure
 <222> (575) .. (576) .. (577)

<220>
 <221> unsure
 <222> (586)

<220>
 <221> unsure
 <222> (594) .. (595)

<220>
 <221> unsure
 <222> (608)

<220>
 <221> unsure
 <222> (619)

<220>
 <221> unsure
 <222> (642)

<220>
 <221> unsure
 <222> (657)

<220>
 <221> unsure
 <222> (660) .. (661)

<220>
 <221> unsure
 <222> (672)

<400> 9

```

ggcacgagct ggctgaaccg acaaacaaca gcaataattc atagttgaag acaggcacag 60
ggcgagaccg ccgtcatgga cactgagacc gaggggaagg cggcggcggt cgaggagatg 120
agggagtggg gcgtcgctct cccaagggtg gagctccacg ccacactcaa cggctccgtc 180
cgcaactcca cctcctaga acttgcaaaa catctaggcg acaaaggagt cattgttttt 240
gaagatgtta aggatgtgat catgaagagt gatagatctc ttccagagtg tttcaagctt 300
tttgatctgt ttcataact tacaactgat catgatacag taacaaggat tgctaaggag 360
gttgtagaag attttgctgc agagaatgtt gtatatattg aaataagaac ancacctaag 420

```

WO 01/09305

PCT/US00/21009

aacantgagg canaggggat gaccaagang ttttacatgg atgctgttat naaggtctga 480
aagcacttga agatttgatg tncaaattat tgggtccnat ttcagnacaa atgaaacnct 540
tantcnaact tttgatgggn ccnaaganan gnaannntat tttagncctt ctannattgt 600
tccccanaa atttggttna tggaccgtta cccaccctga antatggcca aggttcntgn 660
nttgcttcgg gnt 673

<210> 10
<211> 46
<212> PRT
<213> Zea mays

<400> 10
Glu Trp Cys Val Ala Leu Pro Lys Val Glu Leu His Ala His Leu Asn
1 5 10 15
Gly Ser Val Arg Asn Ser Thr Leu Leu Glu Leu Ala Lys His Leu Gly
20 25 30

Asp Lys Gly Val Ile Val Phe Glu Asp Val Lys Asp Val Ile
35 40 45

<210> 11
<211> 530
<212> DNA
<213> Glycine max

<220>
<221> unsure
<222> (475)

<220>
<221> unsure
<222> (477)

<220>
<221> unsure
<222> (526)

<400> 11
gttactattg acgtcgtttc gttttcattt aagaacaacg gtttttgaca gaggtatttc 60
ttcaagatta caaacagatt attgcagctc gaacagggcc aatcgaagca tacggagtaa 120
tacattttact ttgcaatctc gagtccttca cacaaaatct tttcaatata ataaatcaaa 180
atgtgtggtg aaaatatgaa gcagttcctc aaggagctcc caaaaatgtga gcatcacatt 240
catatcgagg ggtctctgtc tccagctctg ctgttcgaat tggcaaagac aaacaacatc 300
gcccttcccc actctgcggc tgatgcctct ttcaaactc cccaagaact cgagtctcgc 360
tacgaacggt ttacttctct caacgatttc ctccattact attacattgg catgtcaagt 420
gttaataaac ccctggcgac taatgaaaag cttggcctat ggaatatctc acaanangaa 480
atcgcgacgg gggttcaaca atgctggaaa ttttcttccg attcanaagg 530

<210> 12
<211> 37
<212> PRT
<213> Glycine max

<400> 12
Gln Phe Leu Lys Glu Leu Pro Lys Cys Glu His His Ile His Ile Glu
1 5 10 15
Gly Ser Leu Ser Pro Ala Leu Leu Phe Glu Leu Ala Lys Thr Asn Asn
20 25 30

Ile Ala Leu Pro Asp
35

<210> 13
<211> 2573
<212> DNA
<213> Zea mays

<220>
<221> unsure
<222> (4)..(5)

<220>
<221> unsure
<222> (9)

<220>
<221> unsure
<222> (12)

<220>
<221> unsure
<222> (14)

<220>
<221> unsure
<222> (17)..(18)

<220>
<221> unsure
<222> (24)

<220>
<221> unsure
<222> (45)

<220>
<221> unsure
<222> (54)

<220>
<221> unsure
<222> (57)

<220>
<221> unsure
<222> (63)

<220>
<221> unsure
<222> (69)

<220>
<221> unsure
<222> (73)..(74)

WO 01/09305

PCT/US00/21009

<220>
<221> unsure
<222> (81)

<220>
<221> unsure
<222> (85)

<220>
<221> unsure
<222> (94)

<220>
<221> unsure
<222> (118)..(119)

<220>
<221> unsure
<222> (122)

<220>
<221> unsure
<222> (129)..(130)

<220>
<221> unsure
<222> (142)

<220>
<221> unsure
<222> (165)

<220>
<221> unsure
<222> (167)..(168)

<220>
<221> unsure
<222> (176)

<220>
<221> unsure
<222> (179)

<220>
<221> unsure
<222> (190)

<220>
<221> unsure
<222> (202)..(203)

<220>
<221> unsure
<222> (214)

<220>
<221> unsure
<222> (218)

<220>
<221> unsure
<222> (230)

<220>
<221> unsure
<222> (235)

<220>
<221> unsure
<222> (241)

<220>
<221> unsure
<222> (244)

<220>
<221> unsure
<222> (250)

<220>
<221> unsure
<222> (277)

<220>
<221> unsure
<222> (293)

<220>
<221> unsure
<222> (315)

<220>
<221> unsure
<222> (320)

<220>
<221> unsure
<222> (328)

<220>
<221> unsure
<222> (357)

<220>
<221> unsure
<222> (367)

<220>
<221> unsure
<222> (411)

<220>
<221> unsure
<222> (497)

<400> 13
cggnngtting gncnggncg aggnnttcgta gtatatattggt gaggnkgaga gggngttnaac 60
tcnttccana ggncgggaa ncgtngggta agcnttggtt ccsgcctttt tggtttannt 120
anggcggann cagggggggg gngggatcgc cgccgggggt tcctngnnaa gaggangang 180

```

accccaattn ggttgggggtg gnngggcccg cactttanag ggtgragggg taacnccagg 240
nagntttctn cagataccccc aggggttrct agtctgnacg tgggcccggc cgnacagtaaa 300
caacttttgc gggtnnggtn gaataggncg ggttgaaata attagacctt aagtcanca 360
agtctcntcc tgccagtgc agtgaaaatg ggttcagatg aggatgattc nagacaagg 420
agtggtaaac tttgacaatg gctaccatgg acagaagtga accctggaag gagaacgcaa 480
aggaaaatgc attgtgnaaa atggggctgc cgagcacgag cagcaaaactt gatacgggtca 540
cgcagtaaat ccaataatct tcatgcagtt caacctgacc cagttgctgc agatattcta 600
cgaaaagaac ctcagcaaga atcatttgtc aagctgctaa ctactccaaa ggagattccg 660
actgctgatg aaattgaggt gttcaaaaatc cttcagaagt gcctcgagtt aagagactct 720
tatctcttta gagaggaggt tgctccatgg gagaaggagg tcataaatga cccctgtact 780
ccaaaacctc accccaaccc gttcacttat gtgctgaac caaagtcaga gcatgttttc 840
caaaactgtt atggcggttat ccatgtttat gcggataaag attgtacgga gagcatttat 900
cctgtggctg atgctacaac cttcttcaat gacttgcatt atattctccg agtaacggct 960
gcagggaaca caagaactgt ctgccataat cggttaaatc ttcttgagca taagttttaa 1020
ttccatctga tgttaaattg ggatagggaa ttcttgccc agaagactgc cccacatcgt 1080
gattttttaca atgtcaggaa ggttgacact catgttcac attcagcatg catgaatcaa 1140
aaacatctgt tgaggttcat aaaatccaaa ctaagaaaag aacctgatg ggtggtcatt 1200
ttcagagatg gtacttatat gactttaaaa gaggttttg agagcttgg ctttaactgg 1260
tatgatctga atgttgattt gctagatgtc catgcagaca aaagcacatt tcatcgtttt 1320
gacaaattca atctaaaata caatccatgt ggccaaagta ggctcagaga aattttcttc 1380
aaacaagata atcttattca aggcctgttt cttgctgagt tgacaaagca agttttctct 1440
gacctttctg ctagcaaaata tcagatggca gaatatagga ttcaaatcta cggaaggaaa 1500
cagagtgaat gggaccaact tgcaagttgg atagtgaaca atgaattgca cagtggaaat 1560
gttgtctggc tgggttcagat tccacgctta tataatgtgt acaaggaaat gggatcgtt 1620
acatcattcc aaaatcttct tgacaacatt ttcgttcttc tttttgaggt tactattgat 1680
ccagcttcac acccacagct ccatgtcttc ctgaagcagg ttgtagggtt ggacctggtt 1740
gatgatgaaa gtaaaccaga aaggcgtcca acaaagcaca tgcccacacc tgaacagtgg 1800
accaatgtgt tcaaccctgc attttcatat tatgctgact actgctatgc taacttattc 1860
accctaaaca agctgctgta gtcaaaggga atgaccacta tcaaattccg tccacatgct 1920
ggagaggctg gagatgttga tcaattggca gcgacatttc ttctctgtca caacatatca 1980
catggaatta atctaaggaa gtctcctgtg cttcagtact tgtactatct tggtcagatt 2040
ggtctggcga tgtcccatg gagcaacaac tccttatftc ttgactatca tcgcaacct 2100
tttccaacgt tcttccaacg aggtctgaat gtctcattat ctacggatga ccctttgcaa 2160
attcacctga caaaagaacc attggtggaa gaatacagca ttgctgcttc gctgtggaag 2220
ctcagttctt gtgatttatg cgaaattgcg aggaactctg tttaccaatc tgggttttca 2280
catgctctca aggcgcactg gattggttaag aactacttca aaagaggacc tgctggaaat 2340
gatattcaca gaaccaatgt accgcacatc agggttcaat ttagagagat gatctggaga 2400
aatgaaatga aactagtgt ctctgacaat gagacttaa taccagacga gctggacctg 2460
taagatgtcc agctcgtgt ataccagacg agttgcgttg tagctgctat gggaattata 2520
cttcatgttt tggatatgctt tcttatctta tggcaaatc aacttcgaac ttc 2573

```

<210> 14

<211> 603

<212> PRT

<213> Zea mays

<220>

<221> UNSURE

<222> (15)

<400> 14

Glu Ile Pro Thr Ala Asp Glu Ile Glu Val Phe Lys Ile Leu Xaa Lys
1 5 10 15

Cys Leu Glu Leu Arg Asp Ser Tyr Leu Phe Arg Glu Glu Val Ala Pro
20 25 30

Trp Glu Lys Glu Val Ile Asn Asp Pro Cys Thr Pro Lys Pro Asn Pro
35 40 45

Asn Pro Phe Thr Tyr Val Pro Glu Pro Lys Ser Glu His Val Phe Gln
 50 55 60
 Thr Val Asp Gly Val Ile His Val Tyr Ala Asp Lys Asp Cys Thr Glu
 65 70 75 80
 Ser Ile Tyr Pro Val Ala Asp Ala Thr Thr Phe Phe Thr Asp Leu His
 85 90 95
 Tyr Ile Leu Arg Val Thr Ala Ala Gly Asn Thr Arg Thr Val Cys His
 100 105 110
 Asn Arg Leu Asn Leu Leu Glu His Lys Phe Lys Phe His Leu Met Leu
 115 120 125
 Asn Ala Asp Arg Glu Phe Leu Ala Gln Lys Thr Ala Pro His Arg Asp
 130 135 140
 Phe Tyr Asn Val Arg Lys Val Asp Thr His Val His His Ser Ala Cys
 145 150 155 160
 Met Asn Gln Lys His Leu Leu Arg Phe Ile Lys Ser Lys Leu Arg Lys
 165 170 175
 Glu Pro Asp Glu Val Val Ile Phe Arg Asp Gly Thr Tyr Met Thr Leu
 180 185 190
 Lys Glu Val Phe Glu Ser Leu Asp Leu Thr Gly Tyr Asp Leu Asn Val
 195 200 205
 Asp Leu Leu Asp Val His Ala Asp Lys Ser Thr Phe His Arg Phe Asp
 210 215 220
 Lys Phe Asn Leu Lys Tyr Asn Pro Cys Gly Gln Ser Arg Leu Arg Glu
 225 230 235 240
 Ile Phe Leu Lys Gln Asp Asn Leu Ile Gln Gly Arg Phe Leu Ala Glu
 245 250 255
 Leu Thr Lys Gln Val Phe Ser Asp Leu Ser Ala Ser Lys Tyr Gln Met
 260 265 270
 Ala Glu Tyr Arg Ile Ser Ile Tyr Gly Arg Lys Gln Ser Glu Trp Asp
 275 280 285
 Gln Leu Ala Ser Trp Ile Val Asn Asn Glu Leu His Ser Gly Asn Val
 290 295 300
 Val Trp Leu Val Gln Ile Pro Arg Leu Tyr Asn Val Tyr Lys Glu Met
 305 310 315 320
 Gly Ile Val Thr Ser Phe Gln Asn Leu Leu Asp Asn Ile Phe Val Pro
 325 330 335
 Leu Phe Glu Val Thr Ile Asp Pro Ala Ser His Pro Gln Leu His Val
 340 345 350
 Phe Leu Lys Gln Val Val Gly Leu Asp Leu Val Asp Asp Glu Ser Lys
 355 360 365

Pro Glu Arg Arg Pro Thr Lys His Met Pro Thr Pro Glu Gln Trp Thr
 370 375 380
 Asn Val Phe Asn Pro Ala Phe Ser Tyr Tyr Ala Tyr Tyr Cys Tyr Ala
 385 390 395 400
 Asn Leu Phe Thr Leu Asn Lys Leu Arg Glu Ser Lys Gly Met Thr Thr
 405 410 415
 Ile Lys Phe Arg Pro His Ala Gly Glu Ala Gly Asp Val Asp His Leu
 420 425 430
 Ala Ala Thr Phe Leu Leu Cys His Asn Ile Ser His Gly Ile Asn Leu
 435 440 445
 Arg Lys Ser Pro Val Leu Gln Tyr Leu Tyr Tyr Leu Gly Gln Ile Gly
 450 455 460
 Leu Ala Met Ser Pro Leu Ser Asn Asn Ser Leu Phe Leu Asp Tyr His
 465 470 475 480
 Arg Asn Pro Phe Pro Thr Phe Phe Gln Arg Gly Leu Asn Val Ser Leu
 485 490 495
 Ser Thr Asp Asp Pro Leu Gln Ile His Leu Thr Lys Glu Pro Leu Val
 500 505 510
 Glu Glu Tyr Ser Ile Ala Ala Ser Leu Trp Lys Leu Ser Ser Cys Asp
 515 520 525
 Leu Cys Glu Ile Ala Arg Asn Ser Val Tyr Gln Ser Gly Phe Ser His
 530 535 540
 Ala Leu Lys Ala His Trp Ile Gly Lys Asn Tyr Phe Lys Arg Gly Pro
 545 550 555 560
 Ala Gly Asn Asp Ile His Arg Thr Asn Val Pro His Ile Arg Val Gln
 565 570 575
 Phe Arg Glu Met Ile Trp Arg Asn Glu Met Lys Leu Val Tyr Ser Asp
 580 585 590
 Asn Glu Ile Leu Ile Pro Asp Glu Leu Asp Leu
 595 600

<210> 15

<211> 2782

<212> DNA

<213> Oryza sativa

<400> 15

accccacgcg gaggcggaga gcggagtggc ggcgggatgg actccacctc cgccctccac 60
 ctgcgcgtcg ccacctctct cggcgctctc ttgcgcgcgc cctccgccta ctatatgcac 120
 cgcaagaccc tcgaccagct cctccgcttc gcccgctccc ttgaccgcga ccaccgccgc 180
 cgcaaccgcc acctcctcga cgccgacgac gacgatgacg acgacctcc cagagaccac 240
 gatcgccgca ccaccttcc catcccaccg ggccttccgc caattcacac cggccgagaa 300
 ggaaagccaa ttatctcacc agcttccacc aaaagagttg gacctttggt tagacctact 360
 acaccaagat cccctgttcc tactgtcagt gcatttgaaa ctattgaaga ttcagatgac 420

WO 01/09305

PCT/US00/21009

```

gatgatgagg aatattgccc cagatgccaa aaacaatgcc ggtttccttg ctcacaaaat 480
ggaacgatat tggatcagat ccccttccgg gtaaagcaag tcagaatggg gacacaaaac 540
cagtaccatc aacaaacatg attagatctc aaagtgcac aggcagtctg catggggccc 600
agcacaaatcc agttgcagct gatattcttc gaaaggaacc tgaacatgag actttcagta 660
ggatcaatat aacagctgtt gagactccat ctctgatga aattgaagca tacaaggttc 720
ttcagaaatg tcttgagcta cgagagaagt acatgttttag agaagaagtt gctccatggg 780
agaaggaaat cataactgat cctagtactc caaaacctaa tcctaaccct ttctattacg 840
agcagcagac taaaactgaa catcattttg aaatgggtga tgggtgttatt catgtatacc 900
ccaataaaga cgctaaagaa agaatctatc ctgttgctga tgctactacc ttttttactg 960
atatgcaacta tatccttcgt gtgttggtg ctggggatat tcgaactgta tgttataaac 1020
gtttaaatct tctagaacag aaattcaatc ttcatttgat ggtcaatgcc gatagagaac 1080
tacttgctca gaaagctgca ccccatcggg acttctacaa tgtcaggaag gttgatactc 1140
atgttcatac ctctgcatgc atgaatcaga gagattttatc aagtcgaagt 1200
tgaggaaaga acctgacgag gttgtgattt ttagagatgg tacctatttg actcttaagg 1260
aggtttttga gagtttggac ttgactgggt atgacctcaa tgttgatctc ttagatgtgc 1320
atgccgataa aagtacattc catcgctttg acaagttcaa tttgaagtat aatccttggtg 1380
gccaatcccc gctgagggag atctttctta aacaggacaa ccttattcaa ggccgatttc 1440
ttgctgaatt gacaaaagaa gtattttctg atcttgaagc aagtaaatat cagatggctg 1500
agtatagaat atctatctat gggagaaaga aaagtgaagt ggatcagatg gcaagctgga 1560
tagtgaataa tgaattgtac agcgagaagt ttgtttgggt aattcagatt cctcggatat 1620
acaatgtata cagggagatg ggaacaatca attctttcca gaacctcctt gacaatattt 1680
ttctgctctt ttttgaagta actgttgatc ctgcttcaca tcctcagctc catgttttct 1740
tgcaacaggt cgttgggctg gatttagtgg atgatgaaag caaaccagag agacgcccaa 1800
caaaacacat gectacacct gagcaatgga ctaatgtttt caatccagca tatgcatatt 1860
atgtgtacta ttgttatgct aacttgtaca cgctgaacaa gcttcgtgag tccaagggta 1920
tgacaacaat caaacttcgt ccacactgtg gggaggctgg agatattgat catcttgctg 1980
cagcatttct tacttctcat aatattgctc acgggggttaa tttaaagaag tcccctgtcc 2040
tccagtatct gtattaccta gctcagattg gtcttgccat gtctcctttg agcaacaact 2100
cattgtttat tgattatcac cgaaaccctt tcccaacatt tttcctaaga ggccttaacg 2160
tttctctatc aaccgatgac cctttgcaaa ttcacctgac aaaagaacct ttggttgaag 2220
aatatagcat cgctgcttcg ctgtggaagc taagttcatg cgacctatgt gaaattgcta 2280
ggaattctgt gtaccagtct ggtttctctc ataggtcaa gtcacactgg attgggagaa 2340
actactacaa aagaggtcat gatggcaatg acattcacca gacaaatggt cctcacatca 2400
ggattgaatt ccgacacact atttggaag aagaaatgga gctaatacat ctgaggaatg 2460
ttgatatacc ggaagaaatt gataggtgaa gacctggcaa gaattttgca aaccctgaag 2520
ttacttgggt gttgatgatg gtcttggaag gcaccccatc ttcctaccat aaactttcca 2580
ggtacaacca agaccgtgcg gtttctactt gcttgcgga gggaggagaa agggatctag 2640
gatgattcta cttttcgatg aatctccgta gcgtgttgcg ttccctagta gtaggatttt 2700
gataaaagaa attatgttag gactgaggcc gtaccataaa ataagaaaga tttgagtcatt 2760
ggaatactgg aagtttaaac ct 2782

```

<210> 16

<211> 681

<212> PRT

<213> Oryza sativa

<400> 16

Met Pro Lys Thr Met Pro Val Ser Leu Leu Thr Lys Trp Asn Asp Ile
 1 5 10 15

Gly Ser Asp Pro Leu Pro Gly Lys Ala Ser Gln Asn Gly Asp Thr Lys
 20 25 30

Pro Val Pro Ser Thr Asn Met Ile Arg Ser Gln Ser Ala Thr Gly Ser
 35 40 45

Leu His Gly Ala Gln His Asn Pro Val Ala Ala Asp Ile Leu Arg Lys
 50 55 60

WO 01/09305

PCT/US00/21009

Glu	Pro	Glu	His	Glu	Thr	Phe	Ser	Arg	Ile	Asn	Ile	Thr	Ala	Val	Glu		
65					70					75					80		
Thr	Pro	Ser	Pro	Asp	Glu	Ile	Glu	Ala	Tyr	Lys	Val	Leu	Gln	Lys	Cys		
				85					90					95			
Leu	Glu	Leu	Arg	Glu	Lys	Tyr	Met	Phe	Arg	Glu	Glu	Val	Ala	Pro	Trp		
			100					105					110				
Glu	Lys	Glu	Ile	Ile	Thr	Asp	Pro	Ser	Thr	Pro	Lys	Pro	Asn	Pro	Asn		
	115						120					125					
Pro	Phe	Tyr	Tyr	Glu	Gln	Gln	Thr	Lys	Thr	Glu	His	His	Phe	Glu	Met		
	130						135					140					
Val	Asp	Gly	Val	Ile	His	Val	Tyr	Pro	Asn	Lys	Asp	Ala	Lys	Glu	Arg		
145					150					155					160		
Ile	Tyr	Pro	Val	Ala	Asp	Ala	Thr	Thr	Phe	Phe	Thr	Asp	Met	His	Tyr		
				165					170					175			
Ile	Leu	Arg	Val	Leu	Ala	Ala	Gly	Asp	Ile	Arg	Thr	Val	Cys	Tyr	Lys		
			180					185					190				
Arg	Leu	Asn	Leu	Leu	Glu	Gln	Lys	Phe	Asn	Leu	His	Leu	Met	Val	Asn		
		195					200					205					
Ala	Asp	Arg	Glu	Leu	Leu	Ala	Gln	Lys	Ala	Ala	Pro	His	Arg	Asp	Phe		
	210					215					220						
Tyr	Asn	Val	Arg	Lys	Val	Asp	Thr	His	Val	His	His	Ser	Ala	Cys	Met		
225					230					235					240		
Asn	Gln	Lys	His	Leu	Leu	Arg	Phe	Ile	Lys	Ser	Lys	Leu	Arg	Lys	Glu		
				245					250					255			
Pro	Asp	Glu	Val	Val	Ile	Phe	Arg	Asp	Gly	Thr	Tyr	Leu	Thr	Leu	Lys		
			260					265					270				
Glu	Val	Phe	Glu	Ser	Leu	Asp	Leu	Thr	Gly	Tyr	Asp	Leu	Asn	Val	Asp		
	275						280					285					
Leu	Leu	Asp	Val	His	Ala	Asp	Lys	Ser	Thr	Phe	His	Arg	Phe	Asp	Lys		
	290					295					300						
Phe	Asn	Leu	Lys	Tyr	Asn	Pro	Cys	Gly	Gln	Ser	Arg	Leu	Arg	Glu	Ile		
305					310					315					320		
Phe	Leu	Lys	Gln	Asp	Asn	Leu	Ile	Gln	Gly	Arg	Phe	Leu	Ala	Glu	Leu		
				325					330					335			
Thr	Lys	Glu	Val	Phe	Ser	Asp	Leu	Glu	Ala	Ser	Lys	Tyr	Gln	Met	Ala		
			340					345						350			
Glu	Tyr	Arg	Ile	Ser	Ile	Tyr	Gly	Arg	Lys	Lys	Ser	Glu	Trp	Asp	Gln		
	355						360					365					
Met	Ala	Ser	Trp	Ile	Val	Asn	Asn	Glu	Leu	Tyr	Ser	Glu	Asn	Val	Val		
	370					375					380						

PCT/US00/21009

Trp 385	Leu	Ile	Gln	Ile	Pro 390	Arg	Ile	Tyr	Asn	Val 395	Tyr	Arg	Glu	Met	Gly 400
Thr	Ile	Asn	Ser	Phe 405	Gln	Asn	Leu	Leu	Asp 410	Asn	Ile	Phe	Leu	Pro 415	Leu
Phe	Glu	Val	Thr 420	Val	Asp	Pro	Ala	Ser 425	His	Pro	Gln	Leu	His 430	Val	Phe
Leu	Gln	Gln	Val 435	Val	Gly	Leu	Asp 440	Leu	Val	Asp	Asp	Glu 445	Ser	Lys	Pro
Glu	Arg 450	Arg	Pro	Thr	Lys 455	His	Met	Pro	Thr	Pro 460	Glu	Gln	Trp	Thr	Asn
Val 465	Phe	Asn	Pro	Ala	Tyr 470	Ala	Tyr	Tyr	Val	Tyr 475	Tyr	Cys	Tyr	Ala	Asn 480
Leu	Tyr	Thr	Leu 485	Asn	Lys	Leu	Arg	Glu 490	Ser	Lys	Gly	Met	Thr	Thr 495	Ile
Lys	Leu	Arg	Pro 500	His	Cys	Gly	Glu	Ala 505	Gly	Asp	Ile	Asp	His 510	Leu	Ala
Ala	Ala	Phe 515	Leu	Thr	Ser	His	Asn 520	Ile	Ala	His	Gly	Val 525	Asn	Leu	Lys
Lys	Ser 530	Pro	Val	Leu	Gln	Tyr 535	Leu	Tyr	Tyr	Leu	Ala 540	Gln	Ile	Gly	Leu
Ala 545	Met	Ser	Pro	Leu	Ser 550	Asn	Asn	Ser	Leu	Phe 555	Ile	Asp	Tyr	His	Arg 560
Asn	Pro	Phe	Pro 565	Thr	Phe	Phe	Leu	Arg	Gly 570	Leu	Asn	Val	Ser	Leu 575	Ser
Thr	Asp	Asp	Pro 580	Leu	Gln	Ile	His	Leu 585	Thr	Lys	Glu	Pro	Leu 590	Val	Glu
Glu	Tyr 595	Ser	Ile	Ala	Ala	Ser	Leu 600	Trp	Lys	Leu	Ser 605	Ser	Cys	Asp	Leu
Cys 610	Glu	Ile	Ala	Arg	Asn	Ser 615	Val	Tyr	Gln	Ser	Gly 620	Phe	Ser	His	Arg
Leu 625	Lys	Ser	His	Trp	Ile 630	Gly	Arg	Asn	Tyr	Tyr 635	Lys	Arg	Gly	His	Asp 640
Gly	Asn	Asp	Ile 645	His	Gln	Thr	Asn	Val	Pro 650	His	Ile	Arg	Ile	Glu 655	Phe
Arg	His	Thr	Ile 660	Trp	Lys	Glu	Glu	Met 665	Glu	Leu	Ile	His	Leu 670	Arg	Asn
Val	Asp 675	Ile	Pro	Glu	Glu	Ile	Asp	Arg 680							

<210> 17
<211> 2482

WO 01/09305

PCT/US00/21009

<212> DNA
 <213> Glycine max

<400> 17

```

gcacgagctg ggagtgtttt cgcagttttc actcactgtt cagtagtagg gtttttcttt 60
atcccttttt ctctctcttt ctctctttca ccacttcaac acaacgctca tatttcattc 120
attttcgtga aggcgcacaaac gattttcagtt aaagagagaaa actcgggggaa gagagataga 180
gagagtctgc gattgatcat acatggatac gcacgcggtg catttgggccc tggcggcgct 240
cgtcggagcc tccgtcgtgg ccgtgtcggc gtactacatg caccgcaaga cgctggcgca 300
gctgctggag ttccgcgcgta cggtcgagag ggaggctgcc gccggcggtc ccgacgctga 360
atcgccgcgc gccacgcgca agaagcgccg gggcagctcc aggaagcgcc gcaacggcgg 420
ataccgcgcg ggctccgcgt cgctgccgga cgtcacggcg atctctggcg ggttcgacgg 480
ggacgagaag cggaacgggc ccggtgcacg tcgaggggat tccggcgggg ctgccaaagg 540
tgcacacgct tccgggaagg gaaaatcttc caatctgggt cctttaagag aagcttttta 600
agaccaactt cttccaagtc cctgttgcaa gtgccagtgc cttttgaaag tgtagaagga 660
tcagatgatg aagataccat gccagacaaa gttaacttga tactacatat ctgcatgcaa 720
atgggactgg tgggtccagaa ggtaaaatcc catttgagcc tttacctaat catgttaatg 780
ccaatggaga gcagatggca attacaccga gtatgatccg ctctcatagt gtttctggtg 840
acctgcattg tgtgcagcct gatccaatag cagctgacat tctgaggaaa gagccagagc 900
atgaaacttt cacaagattg agaataactg ctcttgaggc tccgtcacct gatgaaattg 960
aagcttatgt gggtctgcaa gaatgccttg aaatgagaaa aagatatgtt tttagagaag 1020
ctgttgctcc gtgggataaa gaagttatat ccgacccag cacacccaag cctaaccag 1080
atccattttt atacattcct gaaggaaatt ctgatcatta ttttgaaatg caagatgggg 1140
ttattcgtgt atatccagat agagatgcaa aagaagagct ttttcctgta gccgatgcaa 1200
ctacattttt cactgatctt catcacttac ttcgagtcac agcagcaggg aatataagaa 1260
ctttatgcca tcataggctc aatcttctag acaaaaaatt caatcttcat ttgatgctaa 1320
atgcggtatg agaatttctt gctcagaaga gtgctccaca tcgagacttc tataatgtta 1380
gaaaagttga tactcatgtc caccactcag catgcatgaa tcagaaacat cttttaagg 1440
tcataaagtc aaagctgaga aaagagcctg atgaggttgt aatatttctga gatgggacat 1500
atctaacgtt ggaagaggtt ttcaagagtt tagatttgct tggatatgac ctcaatgttg 1560
accttttgga cgttcacgca gacaagagta cttttcatcg ctttgataag ttcaatctta 1620
aatacaatcc ttgcggtcaa agtaggctca gggagatatt tcttaagcag gataatctca 1680
ttcaaggtcg ttttcttggt gagttaacta agcaagtgtt ttcagatctt gctgccagta 1740
aatatcagat ggctgaaat agaatatcaa tatatggtag gaagcaaagt gagtgggacc 1800
aactagccag ttggatagtg aataatgatt tgtacagcga gaatgtcgtt tgggtgattc 1860
agcttccacg gttgtacaat gtgtacaaag aaatgggaat tgtgacatca ttccagaaca 1920
tgctcgacaa tattttcatt ccactttttg aggtcactgt caaccagat tcacatctc 1980
agctgcatgt tttcctgaaa cagggtgttg ggttgattt ggttgatgat gaaagcaaac 2040
ctgaaagacg gccaacaaaa cacatgccta cacctgagca atggactaat gttttcaatc 2100
cggcattttc atactatgtc tattactggt atgcaaactt ttacacctta aacaagcttc 2160
gagaatcaaa gggaatgaca acaatcaaat tccgtccaca ttctggagag gctggtgata 2220
ttgaccacct tgcagcaacc tttctcacgg ctcacaacat tgcacatgga atcaatttga 2280
aaaaatctcc tgtgcttcaa tatttatatt atttagccca gattgggctg gcaatgtctc 2340
ctttgagcaa taactcccta ttcttagact accatcgaa tccttttcca atgttcttct 2400
tacggggtct gaatgtgtca ctttctactg atgatcctc ccaaattcac ttaacaaagg 2460
aaccattggt tgaagaatat ag
2482

```

<210> 18
 <211> 595
 <212> PRT
 <213> Glycine max

<400> 18

Leu Asp Thr Thr Tyr Leu His Ala Asn Gly Thr Gly Gly Pro Glu Gly
 1 5 10 15

Lys Ile Pro Phe Glu Pro Leu Pro Asn His Val Asn Ala Asn Gly Glu
 20 25 30

WO 01/09305

PCT/US00/21009

Gln Met Ala Ile Thr Pro Ser Met Ile Arg Ser His Ser Val Ser Gly
 35 40 45
 Asp Leu His Gly Val Gln Pro Asp Pro Ile Ala Ala Asp Ile Leu Arg
 50 55 60
 Lys Glu Pro Glu His Glu Thr Phe Thr Arg Leu Arg Ile Thr Pro Leu
 65 70 75 80
 Glu Ala Pro Ser Pro Asp Glu Ile Glu Ala Tyr Val Val Leu Gln Glu
 85 90 95
 Cys Leu Glu Met Arg Lys Arg Tyr Val Phe Arg Glu Ala Val Ala Pro
 100 105 110
 Trp Asp Lys Glu Val Ile Ser Asp Pro Ser Thr Pro Lys Pro Asn Pro
 115 120 125
 Asp Pro Phe Leu Tyr Ile Pro Glu Gly Asn Ser Asp His Tyr Phe Glu
 130 135 140
 Met Gln Asp Gly Val Ile Arg Val Tyr Pro Asp Arg Asp Ala Lys Glu
 145 150 155 160
 Glu Leu Phe Pro Val Ala Asp Ala Thr Thr Phe Phe Thr Asp Leu His
 165 170 175
 His Leu Leu Arg Val Ile Ala Ala Gly Asn Ile Arg Thr Leu Cys His
 180 185 190
 His Arg Leu Asn Leu Leu Glu Gln Lys Phe Asn Leu His Leu Met Leu
 195 200 205
 Asn Ala Asp Arg Glu Phe Leu Ala Gln Lys Ser Ala Pro His Arg Asp
 210 215 220
 Phe Tyr Asn Val Arg Lys Val Asp Thr His Val His His Ser Ala Cys
 225 230 235 240
 Met Asn Gln Lys His Leu Leu Arg Phe Ile Lys Ser Lys Leu Arg Lys
 245 250 255
 Glu Pro Asp Glu Val Val Ile Phe Arg Asp Gly Thr Tyr Leu Thr Leu
 260 265 270
 Glu Glu Val Phe Lys Ser Leu Asp Leu Ser Gly Tyr Asp Leu Asn Val
 275 280 285
 Asp Leu Leu Asp Val His Ala Asp Lys Ser Thr Phe His Arg Phe Asp
 290 295 300
 Lys Phe Asn Leu Lys Tyr Asn Pro Cys Gly Gln Ser Arg Leu Arg Glu
 305 310 315 320
 Ile Phe Leu Lys Gln Asp Asn Leu Ile Gln Gly Arg Phe Leu Gly Glu
 325 330 335
 Leu Thr Lys Gln Val Phe Ser Asp Leu Ala Ala Ser Lys Tyr Gln Met
 340 345 350

WO 01/09305

PCT/US00/21009

Ala Glu Tyr Arg Ile Ser Ile Tyr Gly Arg Lys Gln Ser Glu Trp Asp
 355 360 365

Gln Leu Ala Ser Trp Ile Val Asn Asn Asp Leu Tyr Ser Glu Asn Val
 370 375 380

Val Trp Leu Ile Gln Leu Pro Arg Leu Tyr Asn Val Tyr Lys Glu Met
 385 390 395 400

Gly Ile Val Thr Ser Phe Gln Asn Met Leu Asp Asn Ile Phe Ile Pro
 405 410 415

Leu Phe Glu Val Thr Val Asn Pro Asp Ser His Pro Gln Leu His Val
 420 425 430

Phe Leu Lys Gln Val Val Gly Leu Asp Leu Val Asp Asp Glu Ser Lys
 435 440 445

Pro Glu Arg Arg Pro Thr Lys His Met Pro Thr Pro Glu Gln Trp Thr
 450 455 460

Asn Val Phe Asn Pro Ala Phe Ser Tyr Tyr Val Tyr Tyr Cys Tyr Ala
 465 470 475 480

Asn Leu Tyr Thr Leu Asn Lys Leu Arg Glu Ser Lys Gly Met Thr Thr
 485 490 495

Ile Lys Phe Arg Pro His Ser Gly Glu Ala Gly Asp Ile Asp His Leu
 500 505 510

Ala Ala Thr Phe Leu Thr Ala His Asn Ile Ala His Gly Ile Asn Leu
 515 520 525

Lys Lys Ser Pro Val Leu Gln Tyr Leu Tyr Tyr Leu Ala Gln Ile Gly
 530 535 540

Leu Ala Met Ser Pro Leu Ser Asn Asn Ser Leu Phe Leu Asp Tyr His
 545 550 555 560

Arg Asn Pro Phe Pro Met Phe Phe Leu Arg Gly Leu Asn Val Ser Leu
 565 570 575

Ser Thr Asp Asp Pro Leu Gln Ile His Leu Thr Lys Glu Pro Leu Val
 580 585 590

Glu Glu Tyr
 595

<210> 19
 <211> 1988
 <212> DNA
 <213> Triticum aestivum

<400> 19
 attcctaatt ccttaacccta atttcacttt tagagccgtg aatcaaaaat caagaggcat 60
 gggtttttccc aaaatgggtc gatggctgtt gttcccaagt cttttagaaa taaagtccga 120
 tcaaaaagga tttatcctgt ttgctgatgc acgagacctt ttccaccgac ttacattatg 180
 ttctccgggt gactgccgcg gggaacacaa gaactgtctg ccataaccga ttgaatcttc 240
 tagaacataa gttcaaattt catctgatgt taaacgcgga caggaggttt ctgcccacaa 300

```

aaactgcacc acatcgtgat ttttacaatg ttaggaaggt cgacactcat gttcaccact 360
cagcatgcat gaatcagaaa catttgctga gattcatcaa gtccaaactg agaaaagaac 420
ctgatgaggt tgtcattttc agagatggta catatatgac tttgaaggag gtttttgaga 480
gcttggaact aactgggtat gacttgaatg ttgatttgct agatgtccat gcggacaaaa 540
gtacgtttca tcgttttgac aaattcaacc ttaaatacaa tccatgtgga caaagtaggc 600
tacgggagat tttccttaaa caggacaatc ttattcaagg acgatttctt gctgagctga 660
cgatgcaagt tttttctgac cttaatgcaa gcaagtatca gatggctgaa tataggattt 720
caatctatgg gaggaagcaa agtgagtggg accaacttgc gagttggata gtaaacaatg 780
aattgtacag tgaaaatgtt gtttggttga ttcagattcc acgcttatat aacgtgtacc 840
agcaaattgg cattgttaca tcatttcaaa atcttcttga caacattttc ctctctctgt 900
ttgaggttac tattgatcca gcttcgcacc cgagcttca tgtcttcta aagcaggtcg 960
taggggttaga tttggttgat gatgaaagta aacctgaaag gcgtccaact aagcacatgc 1020
ctacacctga agaattggacg aatgtcttca acccggcatt ttcattatatt gcatactact 1080
gctatgctaa cttgtacaca ctgaacaagc tgctgagtc aaaggggatg aatactatca 1140
aattccgtcc acatgccggt gaggtgagag acgttgatca cttggcagca acatttcttc 1200
tttgtcacag tatatcacat ggaatcaatt taagggaagtc tctgtgtctt caataacctgt 1260
actaccttgg tcagatttgg ctggcaatgt cccctctcag caacaactcc ttgtttcttg 1320
attaccatcg gaacctttt cctatgtttt tccaacgagg actgaatgtc tcgctgtcca 1380
cgatgatccc attgcaaatt catctgacaa aagagccatt ggtggaagaa tacagcattg 1440
ctgctcgct atggaagctc agttcttgtg atctatgtga aattgcgaga aattctgtgt 1500
atcaatcagg gttttcacat gctctcaagg cacattggat tggcaagaac tactacaaga 1560
gaggcccttc agggaatgat atccacagaa cgaatgtgcc caccatcagg attgaattca 1620
gggacctgat ctggagagac gaaatgcagc tcgtctacct caacaacgtc atcttgctg 1680
acgaggtgga ccagtaagag gcacctaggt gtataagctg tagccgtcgt gggggatgaa 1740
tcatacttcc tccagatgaa taccatctca ccaaacaacc accaccaaaag tggaagaaga 1800
agacctacaa aataatttca gatcgagggt gcggctcacc attgtgctag actagcatta 1860
cagggaggca agtgctcggt gtgaaactgt cgcccttttc gcctgtaaag gattgtaatt 1920
aacaaaggat gctgtgactg ttataacaat atattgctaa taaagtgatg ccgcactgtt 1980
tcgctctg

```

<210> 20

<211> 345

<212> PRT

<213> Triticum aestivum

<400> 20

```

Arg Cys Lys Phe Phe Ser Asp Leu Asn Ala Ser Lys Tyr Gln Met Ala
  1             5             10             15

```

```

Glu Tyr Arg Ile Ser Ile Tyr Gly Arg Lys Gln Ser Glu Trp Asp Gln
      20             25             30

```

```

Leu Ala Ser Trp Ile Val Asn Asn Glu Leu Tyr Ser Glu Asn Val Val
      35             40             45

```

```

Trp Leu Ile Gln Ile Pro Arg Leu Tyr Asn Val Tyr Gln Gln Met Gly
      50             55             60

```

```

Ile Val Thr Ser Phe Gln Asn Leu Leu Asp Asn Ile Phe Leu Pro Leu
      65             70             75             80

```

```

Phe Glu Val Thr Ile Asp Pro Ala Ser His Pro Gln Leu His Val Phe
      85             90             95

```

```

Leu Lys Gln Val Val Gly Leu Asp Leu Val Asp Asp Glu Ser Lys Pro
      100            105            110

```

```

Glu Arg Arg Pro Thr Lys His Met Pro Thr Pro Glu Glu Trp Thr Asn
      115            120            125

```


Val Phe Asn Pro Ala Phe Ser Tyr Tyr Ala Tyr Tyr Cys Tyr Ala Asn
130 135 140

Leu Tyr Thr Leu Asn Lys Leu Arg Glu Ser Lys Gly Met Asn Thr Ile
145 150 155 160

Lys Phe Arg Pro His Ala Gly Glu Ala Gly Asp Val Asp His Leu Ala
165 170 175

Ala Thr Phe Leu Leu Cys His Ser Ile Ser His Gly Ile Asn Leu Arg
180 185 190

Lys Ser Pro Val Leu Gln Tyr Leu Tyr Tyr Leu Gly Gln Ile Gly Leu
195 200 205

Ala Met Ser Pro Leu Ser Asn Asn Ser Leu Phe Leu Asp Tyr His Arg
210 215 220

Asn Pro Phe Pro Met Phe Phe Gln Arg Gly Leu Asn Val Ser Leu Ser
225 230 235 240

Thr Asp Asp Pro Leu Gln Ile His Leu Thr Lys Glu Pro Leu Val Glu
245 250 255

Glu Tyr Ser Ile Ala Ala Ser Leu Trp Lys Leu Ser Ser Cys Asp Leu
260 265 270

Cys Glu Ile Ala Arg Asn Ser Val Tyr Gln Ser Gly Phe Ser His Ala
275 280 285

Leu Lys Ala His Trp Ile Gly Lys Asn Tyr Tyr Lys Arg Gly Pro Ser
290 295 300

Gly Asn Asp Ile His Arg Thr Asn Val Pro Thr Ile Arg Ile Glu Phe
305 310 315 320

Arg Asp Leu Ile Trp Arg Asp Glu Met Gln Leu Val Tyr Leu Asn Asn
325 330 335

Val Ile Leu Pro Asp Glu Val Asp Gln
340 345

<210> 21
<211> 1447
<212> DNA
<213> Glycine max

<400> 21
gcaccagggtt actattgacg tcgtttcggtt ttcattttaag aacaacgggtt tttgacagag 60
gtatttcttc aagattacaa acagattatt gcagctcgaa cagggccaat cgaagcatac 120
ggagtaatac atttactttg caatctcgag tccttcacac aaaatctttt caatacaata 180
aatcaaaatg tgtggtgaaa atatgaagca gttcctcaag gagctcccaa aatgtgagca 240
tcacattcat atcgaggggt ctctgtctcc agctctgctg ttcgatttgg caaagacaaa 300
caacatcgcc cttcccgact ctgcggctga tgcctctttc aaatctcccc aagaactcga 360
gtctcgctac gaacgggttta cttctctcaa cgatttcttc cattactatt acattggcat 420
gtcagtgtta ataaaccctg ccgactatga aagcttggcc tatgaatatc tcacaaaagc 480
aaatcgcgac ggtgttcacc atgctgaaat tttcttcgat ccacaagcac acactgaacg 540
tggaattgca tacaacactg ttgttgaggg tcttttcggct ggactaaagc gcgctgagaa 600

WO 01/09305

PCT/US00/21009

```

ggatttttgt atcacctcaa aactcattct atgctttttg cgacacttgt cggctgagga 660
tgcaaaaact acatatcagg aagcggtttc gttgggtcac ttttcaaacg ggactgtagc 720
tgctattggc cttgatagca gtgaggtcgg tttcccacca gaaattttca gagagattta 780
tgaatctgca gaaaccaagg ggattcatcg aaccgctcac gctgggtgagg aaggtgacac 840
ttcttacatt tccagagcac tgcacatctg caaagttgaa agaattgatc atggaattag 900
gttggctgaa gatgaaaatt tgtaaagcg agtagcggag caggggacaa tgttgacagt 960
ttgccactc agtaacgttc gcttgagggtg tgttgagaat gttggacaat taccaattcg 1020
aaagttcttg gatggaggaa ttaaattcag catcaacagc gacgatccag cttactttgg 1080
tggttacatt ttggataatt atcttgccgt tcaagaagca tttggcttaa atttaaagga 1140
atggaaatat attgcaacca gcgcgattga aggaagttgg tgtgatgatg agagaaaagc 1200
ggtgttgttg agcaaggttg acgcttgccg caaaaagtac gaggcattgc tttgaaagga 1260
ggagtaaaca aaagttaaac actgcggcat tttcgagttt ggatttgatc tgagatttgc 1320
agatatgcag atagactggt ggtgaagaca atatacatct agattgggtc acttcagcct 1380
ttaataattg gcgctggact caagaacaat atctaaatga cacagaaaaa aaaaaaaaaa 1440
aaaaaaa

```

<210> 22
 <211> 355
 <212> PRT
 <213> Glycine max

<400> 22

Met Cys Gly Glu Asn Met Lys Gln Phe Leu Lys Glu Leu Pro Lys Cys
 1 5 10 15

Glu His His Ile His Ile Glu Gly Ser Leu Ser Pro Ala Leu Leu Phe
 20 25 30

Glu Leu Ala Lys Thr Asn Asn Ile Ala Leu Pro Asp Ser Ala Ala Asp
 35 40 45

Ala Ser Phe Lys Ser Pro Gln Glu Leu Glu Ser Arg Tyr Glu Arg Phe
 50 55 60

Thr Ser Leu Asn Asp Phe Leu His Tyr Tyr Tyr Ile Gly Met Ser Val
 65 70 75 80

Leu Ile Asn Pro Ala Asp Tyr Glu Ser Leu Ala Tyr Glu Tyr Leu Thr
 85 90 95

Lys Ala Asn Arg Asp Gly Val His His Ala Glu Ile Phe Phe Asp Pro
 100 105 110

Gln Ala His Thr Glu Arg Gly Ile Ala Tyr Asn Thr Val Val Glu Gly
 115 120 125

Leu Ser Ala Gly Leu Lys Arg Ala Glu Lys Asp Phe Gly Ile Thr Ser
 130 135 140

Lys Leu Ile Leu Cys Phe Leu Arg His Leu Ser Ala Glu Asp Ala Lys
 145 150 155 160

Thr Thr Tyr Gln Glu Ala Val Ser Leu Gly His Phe Ser Asn Gly Thr
 165 170 175

Val Ala Ala Ile Gly Leu Asp Ser Ser Glu Val Gly Phe Pro Pro Glu
 180 185 190

Thr Leu Cys His Arg Arg Leu Val Leu Leu Glu Gln Lys Phe Asn Leu
 115 120 125
 His Leu Met Leu Asn Ala Asp Lys Glu Phe Leu Ala Gln Lys Ser Ala
 130 135 140
 Pro His Arg Asp Phe Tyr Asn Val Arg Lys Val Asp Thr His Val His
 145 150 155 160
 His Ser Ala Cys Met Asn Gln Lys His Leu Leu Arg Phe Ile Lys Ser
 165 170 175
 Lys Leu Arg Lys Glu Pro Asp Glu Val Val Ile Phe Arg Asp Gly Thr
 180 185 190
 Tyr Leu Thr Leu Arg Glu Val Phe Glu Ser Leu Asp Leu Thr Gly Tyr
 195 200 205
 Asp Leu Asn Val Asp Leu Leu Asp Val His Ala Asp Lys Ser Thr Phe
 210 215 220
 His Arg Phe Asp Lys Phe Asn Leu Lys Tyr Asn Pro Cys Gly Gln Ser
 225 230 235 240
 Arg Leu Arg Glu Ile Phe Leu Lys Gln Asp Asn Leu Ile Gln Gly Arg
 245 250 255
 Phe Leu Gly Glu Ile Thr Lys Gln Val Phe Ser Asp Leu Glu Ala Ser
 260 265 270
 Lys Tyr Gln Met Ala Glu Tyr Arg Ile Ser Ile Tyr Gly Arg Lys Met
 275 280 285
 Ser Glu Trp Asp Gln Leu Ala Ser Trp Ile Val Asn Asn Asp Leu Tyr
 290 295 300
 Ser Glu Asn Val Val Trp Leu Ile Gln Leu Pro Arg Leu Tyr Asn Ile
 305 310 315 320
 Tyr Lys Asp Met Gly Ile Val Thr Ser Phe Gln Asn Ile Leu Asp Asn
 325 330 335
 Ile Phe Ile Pro Leu Phe Glu Ala Thr Val Asp Pro Asp Ser His Pro
 340 345 350
 Gln Leu His Val Phe Leu Lys Gln Val Val Gly Phe Asp Leu Val Asp
 355 360 365
 Asp Glu Ser Lys Pro Glu Arg Arg Pro Thr Lys His Met Pro Thr Pro
 370 375 380
 Ala Gln Trp Thr Asn Ala Phe Asn Pro Ala Phe Ser Tyr Tyr Val Tyr
 385 390 395 400
 Tyr Cys Tyr Ala Asn Leu Tyr Val Leu Asn Lys Leu Arg Glu Ser Lys
 405 410 415
 Gly Met Thr Thr Ile Thr Leu Arg Pro His Ser Gly Glu Ala Gly Asp
 420 425 430

Leu Arg Phe Ser Pro Gly Tyr Met Ala Met Ala His Gln Leu Pro Val
 100 105 110
 Ala Gly Val Val Glu Ala Val Ile Asp Gly Val Arg Glu Gly Cys Arg
 115 120 125
 Thr Phe Gly Val Gln Ala Lys Leu Ile Gly Ile Met Ser Arg Thr Phe
 130 135 140
 Gly Glu Ala Ala Cys Gln Gln Glu Leu Glu Ala Phe Leu Ala His Arg
 145 150 155 160
 Asp Gln Ile Thr Ala Leu Asp Leu Ala Gly Asp Glu Leu Gly Phe Pro
 165 170 175
 Gly Ser Leu Phe Leu Ser His Phe Asn Arg Ala Arg Asp Ala Gly Trp
 180 185 190
 His Ile Thr Val His Ala Gly Glu Ala Ala Gly Pro Glu Ser Ile Trp
 195 200 205
 Gln Ala Ile Arg Glu Leu Gly Ala Glu Arg Ile Gly His Gly Val Lys
 210 215 220
 Ala Ile Glu Asp Arg Ala Leu Met Asp Phe Leu Ala Glu Gln Gln Ile
 225 230 235 240
 Gly Ile Glu Ser Cys Leu Thr Ser Asn Ile Gln Thr Ser Thr Val Ala
 245 250 255
 Glu Leu Ala Ala His Pro Leu Lys Thr Phe Leu Glu His Gly Ile Arg
 260 265 270
 Ala Ser Ile Asn Thr Asp Asp Pro Gly Val Gln Gly Val Asp Ile Ile
 275 280 285
 His Glu Tyr Thr Val Ala Ala Pro Ala Ala Gly Leu Ser Arg Glu Gln
 290 295 300
 Ile Arg Gln Ala Gln Ile Asn Gly Leu Glu Met Ala Phe Leu Ser Ala
 305 310 315 320
 Glu Glu Lys Arg Ala Leu Arg Glu Lys Val Ala Ala Lys
 325 330

GENERAL POWER OF ATTORNEY
(Concerning Several International Patent Applications)

The undersigned, Vernon R. Rice, Vice President and Assistant General Counsel of E. I. DU PONT DE NEMOURS AND COMPANY, 1007 Market Street, Wilmington, Delaware 19898 USA ("DuPont"), hereby confirms that the power to sign for DuPont has been granted to various individuals (as set forth in the attached excerpt from DuPont's Patent Board Rules of Procedure (January 1988), Appendix Section III.A.4), including the Chairman, Vice-Chairman, and those individuals who are Assistant Secretaries of the Patent Board. Currently these Assistant Secretaries are:

Roger A. Bowman
Linda J. Davis
John E. Griffiths

Barbara J. Massie
Miriam D. McConnahey
Deborah A. Meginniss

In addition, the authority to act on behalf of DuPont before the competent International Authorities in connection with any and all international patent applications filed by it with the United States as Receiving Office and to make or receive payments on its behalf is hereby granted to:

Beardell, Lori Y.	34,293	Katz, Elliott A.	26,396
Belopolsky, Inna	43,319	Kelly, Patricia L.	39,247
Benjamin, Steven C.	36,087	King, Karen K.	34,850
Birch, Linda D.	38,719	Kuller, Mark D.	31,925
Bowen, Jr., Alanson G.	24,027	Krukiel, Charles E.	27,344
Christenbury, Lynne M.	30,971	Jarnholm, Arne R.	30,396
Cotreau, William J.	36,490	Langworthy, John A.	32,255
Deitch, Gerald E.	30,457	Lerman, Bart E.	31,897
Deshmukh, Sudhir	33,677	Levitt, Cary A.	31,848
Dobson, Kevin S.	40,296	Magee, Thomas H.	27,355
Duffy, Roseanne R.	33,869	Mayer, Nancy S.	29,190
Edwards, Mark A.	39,542	Medwick, George M.	27,456
Estrin, Barry	26,452	Morrissey, Bruce W.	30,663
Evans, Craig H.	31,825	Reynolds, Stephen E.	37,580
Fair, Tamara L.	35,867	Rizzo, Thomas M.	41,272
Feltham, S. Neil	36,506	Santopietro, Lois A.	36,264
Floyd, Linda Axamethy	33,692	Schaeffer, Andrew L.	33,605
Fricke, Hilmar L.	22,384	Sebree, Chyrtrea J.	45,348
Furr, Robert B.	32,985	Shay, Lucas K.	34,724
Golian, Andrew G.	25,293	Shipley, James E.	32,003
Golian, Paul D.	42,591	Siegehl, Barbara C.	30,684
Gorman, Thomas W.	31,959	Sinnott, Jessica M.	34,015
Gould, David J.	25,338	Steinberg, Michael A.	43,160
Griffiths, John E.	32,647	Steinberg, Thomas W.	37,013
Hamby, Jane O.	32,872	Stevenson, Robert B.	26,039
Hamby, William H.	31,521	Strickland, Frederick D.	39,041
Heiser, David E.	31,366	Tulloch, Rebecca W.	36,297
Hendrickson, John S.	30,847	Walker, P. Michael	32,602
Joung, J. Kenneth	41,881	Wang, Chen	38,650

The undersigned ratifies fully all actions already taken by the above-named individuals in accordance with the authority granted hereby.

E. I. DU PONT DE NEMOURS AND COMPANY

By: _____

Vernon R. Rice

Vernon R. Rice

Vice President and Assistant General Counsel

DECLARATION and POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PURINE METABOLISM GENES IN PLANTS

the specification of which is attached hereto unless the following box is checked:

☒ was filed on **28 JULY 2000** as U.S. Application No. _____ or PCT International Application No. **PCT/US00/21009** and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Application No.	Country	Filing Date	Priority Claimed (Yes/No)
-----------------	---------	-------------	---------------------------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below.

U.S. Provisional Application No.

60/146,473

U.S. Filing Date

30 JULY 1999

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application No.

PCT/US00/21009

Filing Date

28 JULY 2000

Status (patented, pending or abandoned)

Pending

POWER OF ATTORNEY: I hereby appoint the following attorney(s) and/or agent(s) the power to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:Name: **KENING LI**Registration No. **44,872**

Send correspondence and direct telephone calls to:

KENING LI
E. I. du Pont de Nemours and Company
 Legal - Patents
 Wilmington, DE 19898, U.S.A.
Tel. No.
(302) 992-3749Fax No.
(302) 892-7949



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INVENTOR(S)

Full Name of Inventor	Last Name	First Name	Middle Name
CASPAR	CASPAR	TIMOTHY	
	Signature (please sign full name): <i>Timothy Caspar</i>		Date: <i>9/26/00</i>
Residence & Citizenship	City WILMINGTON <i>Yorklyn DE</i>	State or Foreign Country DELAWARE	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 2927 BARLEY MILL ROAD, YORKLYN- DE	City WILMINGTON <i>Yorklyn (DE)</i>	State or Country DELAWARE Zip Code 19736
FALCO	FALCO	GARY	SAVERIO
	Signature (please sign full name): <i>Gary Falco</i>		Date: <i>9/27/00</i>
Residence & Citizenship	City ARDEN <i>DB</i>	State or Foreign Country DELAWARE	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 1902 MILLER ROAD	City ARDEN	State or Country DELAWARE Zip Code 19810
SAKAI	SAKAI	HAJIME	
	Signature (please sign full name): <i>Hajime Sakai</i>		Date: <i>9-29-00</i>
Residence & Citizenship	City WILMINGTON <i>DE</i>	State or Foreign Country DELAWARE	Country of Citizenship GERMANY
Post Office Address	Post Office Address 105 BANBURY DRIVE	City WILMINGTON	State or Country DELAWARE Zip Code 19803

DECLARATION AND POWER OF ATTORNEY - Page 2

Docket No.: **BB1386PCT**

480 Full Name of Inventor	Last Name WENG	First Name ZUDE	Middle Name	
	Signature (please sign full name): 		Date: 10-19-2000	
Residence & Citizenship	City DES PLAINES IL	State or Foreign Country ILLINOIS	Country of Citizenship CHINA	
Post Office Address	Post Office Address 495 LESLIE COURT, APARTMENT 301	City DES PLAINES	State or Country ILLINOIS	Zip Code 60016
500 Full Name of Inventor	Last Name HU	First Name XU	Middle Name	
	Signature (please sign full name): 		Date: 10-13-2000	
Residence & Citizenship	City URBAN DALE IA	State or Foreign Country IOWA	Country of Citizenship CANADA	
Post Office Address	Post Office Address 4700 103RD STREET	City URBAN DALE	State or Country IOWA	Zip Code 50322